Pharmacy Policy System
Advanced Search
  
  
  
  
  
  
  
  
Description
Intent
Policy
BlackBoxWarning
Guidelines
References
  
  
  
  
  
CrossReferences
ApplicableDrugs
  
  
295
  
1/1/2024Rx.01.87CommercialOyenusi, Oluwadamilola

Parathyroid hormone (PTH) and calcitriol are the two major hormones that regulate calcium and phosphate homeostasis.  PTH maintains serum ionized calcium concentrations in a narrow range by stimulating renal tubular calcium reabsorption and bone resorption.  Chronic exposure to high PTH results in bone resorption, however intermittent administration of recombinant human PTH stimulates bone formation to a greater extent than resorption, at least over the first 12 months of therapy.  While PTH is an effective treatment for osteoporosis, it is generally not a first line drug due to route of administration (subcutaneous), long-term safety concerns, and availability of other agents.

Teriparatide is recombinant human PTH. Abaloparatide is a human parathyroid hormone related peptide (PTHrP(1-34)).

 Teriparatide (Forteo®) is indicated:

  • For the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. These include women with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant of previous osteoporosis therapy, based upon physician assessment.
  • To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. These include men with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant to previous osteoporosis therapy, based upon physician assessment.
  • For treatment of osteoporosis associated with sustained systemic glucocorticoid therapy at high risk fracture.

 

Abaloparatide (Tymlos™) is indicated: 
  • For the treatment of postmenopausal women with osteoporosis at high risk of fracture or patients who have failed or are intolerant to other available osteoporosis therapy.
  • For the treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.


The intent of this policy is to communicate the medical necessity criteria for abaloparatide (Tymlos™) and teriparatide (Forteo®) as provided under the member's prescription drug benefit. 


 

 

Primary or hypogonadal osteoporosis in men and Glucocorticoid-induced osteoporosis in men or women

INITIAL CRITERIA: Teriparatide (Forteo®) is approved when ALL of the following are met:

  1. The member is 18 years of age or older; and
  2. ONE of the following:
    1. Primary or hypogonadal osteoporosis in men; or
    2. Glucocorticoid-induced osteoporosis in men or women (daily dose greater than or equal to 5mg prednisone or equivalent for at least 3 months); and
  3. ONE of the following:
    1. Member is high risk for fracture defined by ONE of the following:
      1. History of osteoporotic fractures; or
      2. At least two risk factors for a fracture (e.g., endocrine disorders, gastrointestinal disorders, use of medications associated with low bone mass or bone loss such as corticosteroids); or
      3. Member has a T score of at least -2.5 standard deviations below the young adult mean (T-score ≤ -2.5); or
    2. Inadequate response or inability to tolerate ONE of the following osteoporosis therapies:
      1. Bisphosphonates; or
      2. Hormone replacement therapy; or
      3. Selective estrogen receptor modulators (SERMs); or
      4. Calcitonin salmon (Miacalcin); or
      5. Denosumab (Prolia); and
  4. For Forteo® only, inadequate response or inability to tolerate Teriparatide® manufactured by Alvogen

Initial Authorization duration: 12 months


REAUTHORIZATION CRITERIA: Teriparatide (Forteo®) is re-approved when BOTH of the following are met:

  1. Documentation of positive clinical response; and
  2. ONE of the following:
    1. Cumulative lifetime therapy does not exceed 2 years; or
    2. For Forteo® only, member remains at or has returned to having a high risk for fracture despite a total of 24 months of use for parathyroid hormones

Reauthorization duration: 12 months

​​

Postmenopausal osteoporosis

INITIAL CRITERIA: Abaloparatide (Tymlos™) or teriparatide (Forteo®) is approved when ALL of the following are met:

  1. The member is 18 years of age or older; and
  2. Diagnosis of postmenopausal osteoporosis; and
  3. ONE of the following:
    1. Member is high risk for fracture defined by ONE of the following:
      1. Member has a T score of at least -2.5 standard deviation below the young adult mean (T-score ≤ -2.5); or
      2. History of osteoporotic fractures; or
      3. At least two risk factors for a fracture (e.g., endocrine disorders, gastrointestinal disorders, use of medications associated with low bone mass or bone loss such as corticosteroids); or
    2. Inadequate response or inability to tolerate ONE of the following osteoporosis therapies:
      1. Bisphosphonates; or
      2. Hormone replacement therapy; or
      3. Selective-estrogen receptor modulators (SERMs); or
      4. Calcitonin-salmon (Miacalcin®); or
      5. Denosumab (Prolia®); and
  4. For Forteo® only, inadequate response or inability to tolerate Teriparatide® manufactured by Alvogen​

Initial Authorization duration: 12 months  

REAUTHORIZATION CRITERIA: Abaloparatide (Tymlos™) or teriparatide (Forteo®) is re-approved when BOTH of the following are met:

  1. Documentation of positive clinical response; and
  2. ONE of the following:
    1. Cumulative lifetime therapy does not exceed 2 years; or
    2. For Forteo® only, member remains at or has returned to having a high risk for fracture despite a total of 24 months of use for parathyroid hormones 

Reauthorization duration: 12 months

Increase bone density in men with osteoporosis at high risk for fracture

INITIAL CRITERIA: Abaloparatide (Tymlos®) is approved when ALL of the following are met:

  1. Diagnosis of primary or hypogonadal osteoporosis; and
  2. The member is 18 years of age or older; and
  3. Both of the following:
    1. Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site); and
    2. One of the following:
      1. History of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm; or
      2. Inadequate response or inability to tolerate at least one osteoporosis treatment (e.g., alendronate, zoledronic acid, Prolia [denosumab])

​​​Initial authorization duration: 12 months

REAUTHORIZATION CRITERIA: Abaloparatide (Tymlos®) is re-approved when BOTH of the following are met:
  1. Documentation of positive clinical response; and
  2. Cumulative lifetime therapy does not exceed 2 years

​Reauthorization duration: 12 months​

* Coverage duration of Teriparatide and Tymlos™ is limited to 730-day supply max per lifetime. All other treatment durations are considered Experimental/Investigational.

**Osteoporosis defined as T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR history of osteoporotic fracture (i.e. hip, spine, etc.)


 


N/A

Forteo® (teriparatide) [package insert]. Indianapolis, IN. Lilly USA, LLC. April 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0&type=display. Accessed October 02, 2023.

Prolia® (denosumab) [package insert]. Thousand Oaks, CA. Amgen Inc. January 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88&type=display. Accessed October 02, 2023.

Rosen CJ. Parathyroid hormone/parathyroid hormone-related protein analog for osteoporosis. UpToDate. January 2023. Available at: https://www.uptodate.com/contents/parathyroid-hormone-therapy-for-osteoporosis?source=search_result&search=teriparatide&selectedTitle=4~150. Accessed October 02, 2023.

Tymlos™ (abaloparatide) [package insert]. Waltham, MA: Radius Health, Inc. December 2022. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8&type=display. Accessed October 02, 2023.


 


 

179/14/20239/14/20241/1/2024 1:24 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use
 

Brand Name

Generic Name

Tymlos™

abaloparatide

Forteo®

teriparatide


304
  
1/1/2024Rx.01.148CommercialOyenusi, Oluwadamilola

Actinic keratoses (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. AKs are a concern because the majority of cutaneous squamous cell carcinoma (SCCs) arise from pre-existing AKs, and AKs that will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist.

Cutaneous T cell lymphoma (CTCL) describes a heterogeneous group of neoplasms of skin-homing T cells. CTCL represent approximately 75 to 80 percent of all primary cutaneous lymphomas. Mycosis fungoides (MF) and primary cutaneous CD30+ lymphoproliferative disorders (LPD) account for approximately 90 percent of CTCL.

Ingenol mebutate (Picato®) is indicated for the topical treatment of actinic keratosis (AK).

Ingenol mebutate (Picato®) is an inducer of cell death. The mechanism of action by which ingenol mebutate gel induces cell death in treating AK lesions is unknown.

Diclofenac 3% gel (Solaraze®) is indicated for the topical treatment of AK.

The mechanism of action of diclofenac 3% gel (Solaraze®) in the treatment of AK is unknown.

Tirbanibulin (Klisyri™) is indicated for the topical treatment of actinic keratosis on the face or scalp.

Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown. 

 

Imiquimod (Zyclara™) is indicated for the topical treatment of clinically typical visible or palpable, actinic keratoses (AK) of the full face or baling scalp in immunocompetent adults and the treatment of external genital and perianal warts (EGW)/condyloma acuminata in patients 12 years or older.

 

Imiquimod is a Toll-like receptor 7 agonist. The mechanism of action of Zyclarain treating AK and EGW lesions is unknown.



 

The intent of this policy is to communicate the medical necessity criteria for  ingenol mebutate (Picato®) diclofenac 3% (Solaraze®) tirbanibulin (Klisyri®), and imiquimod (Zyclara™) as provided under the member's prescription drug benefit.

Actinic Keratosis
 
INITIAL CRITERIA Ingenol mebutate (Picato®), diclofenac 3% (Solaraze®) gel, imiquimod (Zyclara®) 3.75%, 2.5%,
or tirbanibulin (Klisyri®) is approved when BOTH of the following are met:

  1. Diagnosis of actinic keratosis; and
  2. Member is 18 years of age or older; and 
  3. ONE of the following:
    1. For imiquimod (Zyclara®) 3.75%, 2.5% only, inadequate response or inability to tolerate imiquimod 5%; or
    2. For Tirbanibulin (Klisyri®) only, inadequate response or inability to tolerate BOTH of the following generics:
      1. Fluorouracil; and
      2. Imiquimod ​​

Initial authorization duration:

  • 30 days for tirbanibulin (Klisyri®), ingenol mebutate (Picato®) imiquimod (Zyclara®) 3.75%, 2.5%.
  • 3 months for diclofenac 3% (Solaraze®)

 REAUTHORIZATION CRITERIA Ingenol mebutate (Picato®), diclofenac 3% (Solaraze®) gel, imiquimod (Zyclara®)

3.75%, 2.5%, or tirbanibulin (Klisyri®) is re-approved when there is documentation of a diagnosis of actinic keratosis at a different site.

Reauthorization duration:

  • 30 days for tirbanibulin (Klisyri®), ingenol mebutate (Picato®) imiquimod (Zyclara®) 3.75%, 2.5%.
  • 3 months for diclofenac 3% (Solaraze®) ​


Genital warts

INITIAL CRITERIA Imiquimod (Zyclara®) 3.75% is approved when BOTH of the following are met:

  1. Diagnosis of genital warts; and
  2. Member is 12 years of age or older; and
  3. Inadequate response or inability to tolerate imiquimod 5%
Initial authorization duration: 30 days

 
REAUTHORIZATION CRITERIA Imiquimod (Zyclara®) 3.75% is re-approved when there is documentation of positive clinical response to therapy.

 

Reauthorization duration: 30 days



Solaraze® (diclofenac 3%):

Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial and stroke, which can be fatal. This risk may occur in treatment and may increase with duration of use.

Solaraze® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Jorizzo J. Treatment of actinic keratosis. UpToDate. July 2021. Available at: https://www.uptodate.com/contents/treatment-of-actinic-keratosis?source=search_result&search=actinic%20keratosis&selectedTitle=1~46. Accessed October 02, 2023.

Picato® (ingenol mebutate) [package insert]. Parsippany, NJ.  Leo Pharma Inc. March 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5accc7a5-8209-4680-b0ae-2a6963500419&type=display.  Accessed October 02, 2023.

Solaraze® (diclofenac 3%) [package insert]. Melville, NY. PharmaDerm. April 2016. Available at:  https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=89a7bfbd-051f-4d87-a642-96b0df81b8e2&type=display. Accessed October 02, 2023.

Willemze R. Classification of primary cutaneous lymphomas. UpToDate. March 2020. Available at: https://www.uptodate.com/contents/classification-of-primary-cutaneous-lymphomas?source=machineLearning&search=CTCL&selectedTitle=7~106&sectionRank=1&anchor=H474649238#H474649238. Accessed October 02, 2023.

Klisyri™ (tirbanibulin) [package insert]. Exton, PA: Almirall; August 2021. Available from: https://klisyrihcp.com/assets/klisyri-prescribing-information.pdf. Accessed October 02, 2023.

Zyclara™ (imiquimod) [package insert]. Bridgewater, NJ: Bausch Health US, LLC; June 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28cd9b5b-680b-480f-b33d-9c5b52bbf03d. Accessed October 02, 2023.​


139/14/20239/14/20241/1/2024 1:25 AMNo presence informationsrv_ppsgw_P

Off-Label Use policy Rx.01.33

Brand NameGeneric Name
Picato®ingenol mebutate

Solaraze®

Klisyri

diclofenac 3%

Tirbanibulin

ZyclaraImiquimod




381
  
7/1/2024Rx.01.226CommercialOyenusi, OluwadamilolaQ1-2024

Seizures can result from a shift in the normal balance of excitation and inhibition within the CNS as well as abnormal brain function. Epilepsy is a chronic medical disorder when two or more unprovoked seizures occur that can't be explained by a medical condition. Abnormal, excessive, and hypersynchronous electrical discharge of neurons in the brain can manifest epileptic seizures. Seizure clusters, also known as acute repetitive seizures are frequent seizure activities that are distinct from a patient's usual seizure pattern. Benzodiazepines are used as a rescue medication for seizure clusters in an outpatient setting.

Midazolam (Nayzilam®) nasal spray is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic  episodes of  frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.

Diazepam (Valtoco®) nasal spray is a  benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

The exact mechanism of action for Nayzilam® and Valtoco® is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.


The intent of this policy is to communicate the medical necessity criteria for midazolam (Nayzilam®) nasal spray and diazepam (Valtoco®) nasal spray as provided under the member's prescription drug benefit.

INITIAL CRITERIA: Midazolam (Nayzilam®) or Diazepam (Valtoco®) nasal spray is approved when ALL of the following are met:

  1. Diagnosis of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern; and
  2. ONE of the following:
    1. For midazol am (Nayzilam®) only, member is 12 years of age or older; or
    2. For diazepam (Valtoco®) only, member is 6 years of age or older; and 
  1. Prescribed by or in consultation with a neurologist/epilepsy specialist


Initial Authorization duration: 2 years

 

REAUTHORIZATION CRITERIA: Midazolam (Nayzilam®) nasal spray or diazepam (Valtoco®) nasal spray is reapproved when there is documentation of positive clinical response to therapy.


Reauthorization duration: 2 years


Benzodiazepines (Nayzilam®, Valtoco®):

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing Nayzilam or Valtoco and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although Nayzilam and Valtoco is indicated only for intermittent use if used more frequently than recommended abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening. For patients using Nayzilam or Valtoco more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue.


Nayzilam® (midazolam nasal spray) [prescribing information]. Smyrna, GA: UCB Inc.; January 2023. Available from: https://www.ucb-usa.com/_up/ucb_usa_com_kopie/documents/Nayzilam_PI.pdf. Accessed April 17, 2024. 

Valtoco® (diazepam nasal spray) [prescribing information]. San Diego, CA: Neurelis, Inc.; January 2023. Available from: https://www.valtoco.com/sites/default/files/Prescribing_Information.pdf. Accessed April 17, 2024.

Jafarpour, Saba & Hirsch, Lawrence & Gaínza-Lein, Marina & Kellinghaus, Christoph & Detyniecki, Kamil. (2018). Seizure cluster: Definition, prevalence, consequences, and management. Seizure. 68. 10.1016/j.seizure.2018.05.013.​


53/14/20243/14/20257/1/2024 1:22 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off-Label Use 

Rx.01.76​ Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit 


Brand nameGeneric name
Nayzilam®Midazolam
Valtoco®Diazepam

NANA
431
  
7/1/2024Rx.01.219CommercialOyenusi, OluwadamilolaQ1-2024

Parkinson's disease (PD) is a neurodegenerative disorder caused by progressive dopamine depletion in the nigrostriatal pathway of the brain.  PD is characterized by manifestations of tremor, bradykinesia, and rigidity. PD is a motor condition that includes neuropsychiatric and other nonmotor manifestations.

The dopamine precursor levodopa is the most effective drug for the symptomatic treatment of PD, however; levodopa-induced complications (eg, motor fluctuations [“wearing off" phenomenon], dyskinesia, dystonia) develop in at least 50% of patients after 5 to 10 years of levodopa treatment. The risk of motor complications increases with higher levodopa doses and younger age of PD onset.

The cause of motor fluctuations is not clear, but it is hypothesized that they evolve as PD progresses because progressive degeneration of the nigrostriatal dopaminergic pathway reduces the ability of nerve terminals to store and release dopamine.  The response to exogenous levodopa becomes more pulse-like due to the inability of the nerve terminals to store and release dopamine.  Levodopa has a short half-life (90 minutes), rapid cycling pharmacokinetics (PK), and erratic intestinal absorption related to slowed intestinal motility.

The four main drugs or classes of drugs that have anti-parkinson activity are monoamine oxidase type B (MAO B) inhibitors, amantadine, dopamine agonists and levodopa. Initial therapy is individualized and requires a flexible trial-and-error approach. Individuals who exhibit mild symptoms with minimal impact on daily life are good candidates for MAO B inhibitor as initial therapy. For individuals with mild to moderate symptoms that impact daily living, either dopamine agonist or levodopa is recommended in individuals younger than 65; levodopa is preferred in those older than 65 years of age. Levodopa is the drug of choice in individuals with moderate to severe symptoms regardless of age.

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is presumably converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of PD

Levodopa (Inbrija™) inhalation powder is indicated for the intermittent treatment of OFF episodes in patients with PD treated with carbidopa/levodopa. 

Istradefylline (Nourianz™) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing “off" episodes. The precise mechanism by which istradefylline exerts its therapeutic effect in PD is unknown.

The mechanism by which apomorphine hydrochloride treats Parkinson Disease is unknown. Apomorphine is a non-ergoline dopamine agonist that has high in-vitro affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, D5, and adrenergic a1D, a2B, and a2C receptors. Activity is suspected to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.

Apomorphine hydrochloride (Kynmobi™) sublingual film is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off" episodes in patients with Parkinson's disease (PD).

Apomorphine hydrochloride (Apokyn®) injection for subcutaneous use is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of hypomobility, “off" episodes (“end-of-dose wearing off" and unpredictable “on/off" episodes) associated with advanced Parkinson's disease.

Adding a catechol-O-methyltransferase (COMT) inhibitor can prolong and potentiate the levodopa effect and thereby reduce "off" time when used as adjunctive therapy with levodopa.



The intent of this policy is to communicate the medical necessity criteria for levodopa inhalation (Inbrija™), istradefylline (Nourianz™), and apomorphine (Apokyn®, Kynmobi™) as provided under the member's prescription drug benefit.
Adjunctive treatment for Parkinson's Disease

Parkinson's Disease
 
INITIAL CRITERIA: Levodopa inhalation (Inbrija™), or istradefylline (Nourianz™) is approved when ALL of the following are met:

  1. Diagnosis of Parkinson's disease and member is experiencing intermittent off episodes; and
  2. Member is 18 years of age or older; and
  3. Concurrent use of carbidopa/levodopa containing product at maximally tolerated dose; and
  4. Prescribed by or in consultation with a neurologist; and
  5. Member had inadequate response or inability to tolerate TWO of the following:
    1. MAO-B Inhibitor (e.g., rasagiline, selegiline); or
    2. Dopamine Agonist (e.g., pramipexole, ropinirole); or
    3. COMT inhibitor (e.g., entacapone)


Initial authorization duration: 2 years

REAUTHORIZATION CRITRIA: Levodopa inhalation (Inbrija®), or istradefylline (Nourianz™) is re-approved when ALL of the following are met:

  1. Documentation of positive clinical response to therapy; and
  2. Concurrent use of carbidopa/levodopa containing product

 
__________________________________________________________________________________________
Advanced Parkinson's Disease


INITIAL CRITERIA: Apomorphine (Apokyn®, Kynmobi™) is approved when ALL of the following are met: 

  1. Diagnosis of advanced Parkinson's disease and member is experiencing intermittent "off" episodes; and
  2. Member is 18 years of age or older; and
  3. One of the following:
    1. Member is receiving medication in combination with other medications for the treatment of Parkinson's disease at maximally tolerated dose (e.g., carbidopa/levodopa, pramipexole, ropinirole, etc…); or
    2. Member has a contraindication or intolerance to other medications for the treatment of Parkinson's disease; and
  1. Member is not using the medication with any 5-HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron); and
  2. For Apomorphine (Apokyn®) inadequate response or inability to tolerate apomorphine (Kynmobi™); and
  3. Prescribed by or in consultation with a neurologist

Initial authorization duration: 2 years

REAUTHORIZATION CRITRIA: Apomorphine (Apokyn®, Kynmobi™) is re-approved with documentation of positive clinical response to therapy.

Reauthorization duration: 2 years


None

Apokyn® (apomorphine hydrochloride injection) [prescribing information]. Louisville, KY: US WorldMeds, LLC.; June 2022. Available from: https://www.apokyn.com/sites/all/themes/apokyn/content/resources/Apokyn_PI.pdf. Accessed April 17, 2024.

Inbrija™ [package insert]. Ardsley, NY. Acorda Therapeutics, Inc. December 2022. Available at: https://www.inbrija.com/prescribing-information.pdf. Accessed April 17, 2024.

Kynmobi™ (apomorphine hydrochloride sublingual film) [prescribing information]. Marlborough, Massachusetts: Sunovion Pharmaceuticals Inc.; September 2022. Available from: https://www.kynmobi.com/Kynmobi-Prescribing-Information.pdf. Accessed April 17, 2024.

Nourianz™ [package insert]. Bedminster, NJ. Kyowa Kirin, Inc., May 2020. Available at: https://www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf. Accessed April 17, 2024.

Chou KL. Clinical manifestations of Parkinson disease. UpToDate Web site. Updated March 2023. www.uptodate.com. Accessed April 17, 2024.

Fox SH, Katzenschlager R, Lim SY, et al; Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248-1266.

Grosset DG, Dhall R, Gurevich T, et al. Long-term pulmonary safety of inhaled levodopa in Parkinson's disease subjects with motor fluctuations: a phase 3 open-label randomized study. Poster presented at: 2nd Pan American Parkinson's Disease and Movement Disorders Congress; June 22-24, 2018; Miami, FL.

Jankovic J. Epidemiology, pathogenesis, and genetics of Parkinson disease. UpToDate Web site. Updated March 223. www.uptodate.com. Accessed April 17, 2024.

LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord. 2016;31(9):1356-65.

LeWitt PA, Hauser RA, Pahwa R, et al; on behalf of the SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-54.

Oertel WH, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson's disease. In: Gilhus NE, Barnes MP, Brainin M, eds. European Handbook of Neurological Management. West Sussex, United Kingdom: Wiley-Blackwell; 2011:237-267.

Spindler MA, Tarsy D. Initial pharmacologic treatment of Parkinson disease. UpToDate Web site. Updated March 2023. www.uptodate.com. Accessed April 17, 2024.

Tarsy D. Medical management of motor fluctuations and dyskinesia in Parkinson disease. UpToDate Web site. Updated March 2023. www.uptodate.com. Accessed April 17, 2024.



113/14/20243/14/20257/1/2024 1:31 AMNo presence informationsrv_ppsgw_P
​Rx.01.33 Off-Label Use

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit
Brand NameGeneric Name
Inbrija™Levodopa inhalation
Nourianz™Istradefylline
Apokyn®Apomorphine
Kynmobi™Apomorphine


NANA
382
  
7/1/2024Rx.01.158CommercialOyenusi, OluwadamilolaQ1-2024

Allergic rhinitis is a persistent condition that typically requires ongoing therapy.  Allergen avoidance along with pharmacologic therapy with nasal corticosteroids and oral antihistamines are standard management.  Allergen immunotherapy is reserved for severe or refractory cases.  Sublingual immunotherapy involves the application of the allergen to the sublingual tissue.  In the case of Odactra™, Oralair®, Grastek®, and Ragwitek®, the allergen is in a sublingual tablet which is self-administered, after the first dose.

The exact mechanism of sublingual allergen immunotherapy has not been fully elucidated.  Allergen extracts given sublingually are primarily taken up by dendritic cells in the mucosa and presented to T cells in the draining lymph nodes. Likely mechanisms of action include activation of T regulatory cells and downregulation of mucosal mast cells. Within the oral and sublingual mucosa, effector cells, such as mast cells, are less numerous, which may account for the lower rates of adverse systemic allergic reactions seen with sublingual immunotherapy.

Timothy grass pollen allergen extract (Grastek®) is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens in persons 5 through 65 years of age.

Short ragweed pollen allergen extract (Ragwitek®) is indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen in individuals 5 through 65 years of age.

Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass mixed pollens allergen extract (Oralair®) is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product in persons 10 through 65 years of age. 

Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mite allergen extract (Odactra™) is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. Odactra™ is approved for use in individuals12 through 65 years of age.


The intent of this policy is to communicate the medical necessity criteria for house dust mite allergen extract (Odactra™), grass pollen allergen extract-5 grass (Oralair®), grass pollen allergen extract-timothy grass (Grastek®), and short ragweed pollen allergen extract (Ragwitek®) as provided under the member’s prescription drug benefit.

INITIAL CRITERIA: Odactra™, Oralair®, Grastek® or Ragwitek® is approved when ALL of the following are met:

  1. FDA approved indication; and
  2. Patient has a positive skin test or in vitro test for ONE of the listed pollen-specific IgE antibodies:
    1. Timothy Grass or cross-reactive grass pollens (GRASTEK® only); or
    2. Any of the five grass species including sweet vernal, orchard perennial rye, timothy or Kentucky blue grass mixed pollens (ORALAIR® only); or
    3. Short ragweed pollen (RAGWITEK® only); or
    4. Dermatophagoides farina or Dermatophagoides pteronyssinus house dust mites (ORDACTRA™ only); and
  3. Prescribed by or in consultation with allergist or immunologist and
  4. ONE of the following:
    1. For Grastek, member is between 5 to 65 years of age; or
    2. For Odactra, member is between 12 to 65 years of age; or
    3. For Oralair, member is between 5 to 65 years of age; or
    4. For Ragwitek, member is between is 5 to 65 years of age; and
  5. Patient does not have any of the following:
    1. Severe, unstable or uncontrolled asthma; or
    2. History of eosinophilic esophagitis; and
  6. Patient has had an inadequate response or inability to tolerate BOTH of the following:
    1. Intranasal corticosteroid; and
    2. Antihistamine


Initial Authorization duration: 1 year 

REAUTHORIZATION CRITERIA: Odactra™, Oralair®, Grastek® or Ragwitek® is re-approved when ALL of the following are met:

  1. Use in the age group supported by FDA labeling; and
  2. Prescribed by or in consultation with allergist or immunologist; and
  3. Patient has experienced improvement in the symptoms of their allergic rhinitis OR a decrease in the number of medications needed to control allergy symptoms 

Reauthorization duration: 1 year 


Severe allergic reactions:

Odactra™, Grastek®, Oralair® and Ragwitek® can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. 

Do not administer Odactra™, Grastek®, Oralair® and Ragwitek® to patients with severe, unstable or uncontrolled asthma. Observe patients in the office for at least 30 minutes following the initial dose.

Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.

Odactra™, Grastek®, Oralair® and Ragwitek® may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.

Odactra™, Grastek®, Oralair® and Ragwitek® may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. 


Creticos PS. Sublingual immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma. UpToDate. Available at: http://www.uptodate.com/contents/sublingual-immunotherapy-for-allergic-rhinoconjunctivitis-and-asthma. Accessed April 17, 2024.

De Shazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. UpToDate. Available at: https://www.uptodate.com/contents/pharmacotherapy-of-allergic-rhinitis?search=pharmacotherapy-of-allergic-rhinitis.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed April 17, 2024.

Grastek® (Timothy grass pollen allergen extract) [package insert]. Whitehouse Station NJ. Merck and Co, Inc. December 2019. Accessed April 17, 2024.

Odactra™ (and house dust mite allergen extract) [package insert]. Whitehouse Station NJ. Merck and Co, Inc. January 2023. Available from: https://www.odactra.com/assets/pdf/odactra-full-pi.pdf. Accessed April 17, 2024.

Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass mixed pollens allergen extract) [package insert]. Lenoir NC. Greer Laboratories, Inc. November 2018. Accessed April 17, 2024.

Ragwitek® (short ragweed pollen allergen extract) [package insert]. Whitehouse Station NJ. Merck and Co, Inc. April 2021. Accessed April 17, 2024. 


143/14/20243/14/20257/1/2024 1:22 AMNo presence informationsrv_ppsgw_P
Rx.01.33  Off- Label Use 
Brand NameGeneric Name
Grastek®grass pollen allergen extract-timothy grass 
Oralair®grass pollen allergen extract-5 grass
Ragwitek®short ragweed pollen allergen extract
Odactra™house dust mite allergen extract

NANA
329
  
1/1/2024Rx.01.267CommercialOyenusi, Oluwadamilola

Testing for genetic mutations in the PIK3CA gene is done at initial MBC diagnosis if tumor is HR+/HER2- following progression on or after an endocrine-based regimen. This gene effects cell growth and development and can contribute to a worse prognosis for patients. Knowledge of the presence of this mutation can inform providers in their treatment selection for these patients.

Alpelisib is a small-molecule phosphatidylinositol-3-kinase (PI3K) inhibitor with selective (and strong) activity against PI3Kα (André 2019). Mutations in the gene encoding the catalytic α-subunit of PI3K (PI3KCA) lead to activation of PI3Kα and Akt-signaling, cellular transformation, and tumor generation. Alpelisib inhibits phosphorylation of PI3K downstream targets (including Akt) and demonstrated activity in cell lines harboring a PIK3CA mutation. When compared with either agent alone, the combination of alpelisib with fulvestrant has synergistic antitumor activity in PIK3CA-mutated, estrogen receptor-positive models.

Activating mutations in PIK3CA may induce a spectrum of overgrowths/malformations comprising clinically recognizable disorders commonly known as PIK3CA-related overgrowth spectrum (PROS). In an animal model PROS phenotype (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal syndrome [CLOVES]), alpelisib inhibited the PI3K pathway, resulting in prevention or improvement of organ abnormalities associated with the disease; findings were reversed following alpelisib withdrawal

Breast cancer, advanced or metastatic: Treatment (in combination with fulvestrant) of HR-positive, HER2-negative, PIK3CA-mutated (as detected by an approved test), advanced or metastatic breast cancer in males and postmenopausal females following progression on or after an endocrine-based regimen.

PIK3CA-related overgrowth spectrum: Treatment of severe manifestations of PIK3CA-related overgrowth spectrum in patients ≥2 years of age who require systemic therapy.



​The intent of this policy is to communicate the medical necessity criteria for Alpelisib (Vijoice®) as provided under the member's prescription drug benefit. 

INITIAL CRITERIA Alpelisib (Vijoice) is approved when ALL of the following are met:

 

  1. Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS); and
  2. Documentation of mutation in the PIK3CA gene; and
  3. Member is 2 years of age or older; and
  4. Documentation of severe clinical manifestations (e.g., Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal [CLOVES], Facial Infiltrating Lipomatosis [FIL], Klippel-Trenaunay Syndrome [KTS], Megalencephaly-Capillary Malformation Polymicrogyria [MCAP]); and
  5. Prescribed by or in consultation with a provider who specialized in the treatment of PROS 

Initial authorization duration: 6 months

 

REAUTHORIZATION CRITERIA Alpelisib (Vijoice®) is re-approved when ALL of the following are met:

 

  1. Documentation of positive clinical response to therapy (e.g., radiological response defined as a ≥ 20% reduction from baseline in the sum of target lesion volume); and
  2. Prescribed by or in consultation with a provider who specializes in the treatment of PROS

​Reauthorization duration: 12 months 


​N/A

André F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.[PubMed 31091374]

Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540-546. doi:10.1038/s41586-018-0217-9[PubMed 29899452]

Vijoice® (alpelisib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2022. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/vijoice.pdf. Accessed October 02, 2023.​



29/14/20239/14/20241/1/2024 1:28 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off Label Use

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit​


Brand NameGeneric Name
Vijoice®Alpelisib


383
  
7/1/2024Rx.01.216CommercialOyenusi, OluwadamilolaQ1-2024

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction. LEMS is associated with reduced acetylcholine (ACh) release from the presynaptic nerve terminals. Antibodies directed against the voltage-gated calcium channel (VGCC) interfere with the normal calcium flux required for the release of ACh from the presynaptic nerve terminal. The most common symptoms of LEMS include proximal muscle weakness, fatigue, autonomic symptoms such as dry mouth, sluggish pupillary light response, erectile dysfunction in men, and reduced tendon reflexes. LEMS patients can be divided into two groups: patients with LEMS associated with underlying malignancy (paraneoplastic LEMS) and those without malignancy (non-paraneoplastic LEMS). For patients with paraneoplastic LEMS, treatment of malignancy may be the only intervention necessary to produce improvement in neurologic symptoms of LEMS.

Amifampridine (Firdapse®) is broad spectrum potassium channel blocker indicated for the treatment of LEMS in adults and pediatric patients 6 years of age and older. It blocks presynaptic voltage-gated potassium channels, prolonging the duration of the presynaptic action potential, lengthening the opening time of the VGCC, and increasing the presynaptic calcium levels. The increased calcium levels lead to an increase in the amount of ACh released. ACh then binds to muscle receptors and results in improved muscle function.    


The intent of this policy is to communicate the medical necessity criteria for amifampridine (Firdapse®) as provided under the member's prescription drug benefit

INITIAL CRITERIA: Amifampridine (Firdapse®) is approved when ALL of the following are met:

  1. Member has a diagnosis of Lambert-Eaton myasthenic syndrome; and
  2. Member is 6 years of age or older and
  3. Neurological symptoms persist after treatment of malignancy when malignancy is present; and
  4. Documentation of symptomatic LEMS that interfere with daily functions (e.g., difficulty climbing stairs, walking up steep hills); and
  5. Prescribed by or in consultation with a neurologist; and
  6. Member does not have history of seizures

Initial authorization duration: 3 months 

CONTINUATION CRITERIA: Amifampridine (Firdapse®) is re-approved when there is documentation of positive clinical response to therapy (e.g., improvement in dynamometry, Timed 25-Foot Walk Test, Timed Up and Go Test)
Reauthorization duration: 2 years


None

Firdapse® (amifampridine) [prescribing information]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.  September 2022. Available at: https://www.firdapse.com/pdfs/firdapse-pi.pdf. Accessed April 17, 2024.

Titulaer MJ, Lang B, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011[a]; 10:1098-1107.

Weinberg DH. Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis. UpToDate Web site. Updated March 2023. www.uptodate.com. Accessed April 17, 2024.


83/14/20243/14/20257/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use
Brand NameGeneric Name
Firdapse®amifampridine phosphate

NANA
263
  
10/1/2023Rx.01.213CommercialOyenusi, Oluwadamilola

Mycobacterium avium complex (MAC) is the most common pulmonary nontuberculous mycobacterial (NTM) infections of the lung in almost all regions of the world. Antimycobacterial treatment is prolonged and potentially difficult to tolerate and should only be considered in individuals who meet the clinical, radiographic, and microbiologic criteria for the diagnosis of nontuberculous mycobacterial infection. Three-drug combination regimen is recommended for those treated for MAC pulmonary disease and treatment is continued until sputum cultures are consecutively negative for at least 12 months.

Amikacin liposome inhalation suspension (Arikayce®) is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.  

​The intent of this policy is to communicate the medical necessity criteria for amikacin liposome inhalation suspension (Arikayce®) as provided under the member's prescription drug benefit.

INITIAL CRITERIA: ​Arikayce® (amikacin liposome inhalation suspension) is approved when ALL of the following are met:

1. Diagnosis of refractory Mycobacterium avium complex (MAC) lung disease; and

2. Member has not achieved negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen therapy; and

3. Documentation that the medication will be used as part of a combination antibacterial regimen; and

4. Member is 18 years of age or older; and

5. Prescribed by or in consultation with a pulmonologist or infectious diseases specialist

Initial authorization duration: 6 months

REAUTHORIZATION CRITERIA: Arikayce® (amikacin liposome inhalation suspension) is re-approved when both of the following are met:

  1. Documentation of positive clinical response to therapy; and
  2. Documentation that the medication will be used as part of a combination antibacterial regimen

Reauthorization duration: 12 months


​WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS

ARIKAYCE has been associated with a risk of increased respiratory adverse reactions, including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.

Arikayce® (amikacin liposome inhalation suspension) [prescribing information]. Bridgewater, NJ. Insmed®. February 2023. Available at: https://www.arikayce.com/pdf/full-prescribing-information.pdf. Accessed June 22, 2023.

Kasperbauer, S. Treatment of Mycobacterium avium complex pulmonary infections in adults. UpToDate Web site. September 2021. www.uptodate.com. Accessed June 22, 2023. ​



56/8/20236/8/202410/1/2023 1:27 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off-Label Use

Brand NameGeneric Name
Arikayce®Amikacin liposome inhalation suspension
293
  
1/1/2024Rx.01.4CommercialOyenusi, Oluwadamilola

Male hypogonadism is characterized by low testosterone levels.  Primary hypogonadism is characterized by low testosterone levels in the setting of elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations.  Examples of primary hypogonadism include, but are not limited to, Klinefelter syndrome, castration (physical or chemical), and trauma.  Secondary hypogonadism, also referred to as hypogonadotropic hypogonadism, is characterized by low testosterone levels in the setting of normal or low LH and FSH.  In this type of hypogonadism, dysfunction of the hypothalamus or pituitary is the underlying etiology.  Examples of hypogonadotopic hypogonadism include, but are not limited to, idiopathic hypogonadotropic hypogonadism, Kallman syndrome, and pituitary tumors, surgery, or destruction.


Gender dysphoria, according to the World Professional Association for Transgender Health (WPATH), is defined as the discomfort arising from incongruence between an individual's gender identity and their external sexual anatomy. The standard of care for individuals affected by gender dysphoria include extensive counseling, hormonal therapy and surgery. Androgen hormone therapy is used to induce physical changes to match gender identify in transgender men (female-to-male, FTM). The goal of therapy is to maintain hormone levels in the normal physiological range for the targeted gender, to stop menses and induce virilization, including a male pattern of sexual and facial hair, change in voice, and male physical contours. Both topical and injectable testosterone products are effective for the management of gender dysphoria.

The active ingredient in all products listed is testosterone. Exogenous testosterone serves to replace testosterone in individuals who are deficient.  Testosterone therapy is indicated for replacement therapy in patients with low testosterone levels due to primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). Testosterone enanthate intramuscular injection and methyltestosterone can also be used to stimulate puberty in carefully selected males with clearly delayed puberty. Methyltestosterone is also indicated for the treatment of metastasis from malignant tumor of breast in women 1 to 5 years postmenopausal with inoperable metastatic skeletal disease.

The intent of this policy is to communicate the medical necessity criteria for Androgel®, Androderm®, Fortesta®, Jatenzo®, Tlando®, Natesto®,  Testim®, Vogelxo®, Xyosted™, Kyzatrex®, methyltestosterone (Methitest®), and generic testosterone products as provided under the member’s prescription drug benefit.

Primary or secondary hypogonadism

INITIAL CRITERIA: Androgel®, generic transdermal testosterone products, Androderm®, Fortesta®, Natesto®, Testim®, Vogelxo®, Xyosted™, testosterone undecanoate (Jatenzo®, Tlando®, Kyzatrex®), or methyltestosterone (Methitest®) is approved when ALL of the following are met:

    1. Diagnosis of primary or secondary hypogonadism; and
    2. Member is 18 years of age or older; and
    3. ONE of the following:
      1. Negative history of prostate and breast cancer; OR
      2. History of prostate cancer status post prostatectomy and documentation that the risk versus benefit has been assessed; and
    1. For Androgel®, Androderm®,  Fortesta®, Natesto®, Testim®, Vogelxo®, Xyosted™, testosterone undecanoate (Jatenzo®, Tlando®, Kyzatrex®), methyltestosterone(Methitest®) only, inadequate response or inability to tolerate generic transdermal testosterone ; and
    2. New users only, low (morning) testosterone level

Initial authorization duration: 2 years

REAUTHORIZATION CRITERIA Androgel®, generic transdermal testosterone products, Androderm®, Fortesta®, Natesto®, Testim®, Vogelxo®, Xyosted™, testosterone undecanoate (Jatenzo®, Tlando®, Kyzatrex®), methyltestosterone (Methitest®) is re-approved when there is documentation of positive clinical response to therapy.

Reauthorization duration: 2 years​

Gender dysphoria

INITIAL CRITERIA Androgel®, generic transdermal testosterone products, Androderm®, Fortesta®, Natesto®, Testim®, Vogelxo®, Xyosted™, testosterone undecanoate (Jatenzo®, Tlando®, Kyzatrex®), or methyltestosterone (Methitest®) is approved for use as hormone therapy in children, adolescents, and adults with gender dysphoria when there is documentation of persistent, well-documented gender dysphoria diagnosed in accordance with criteria established in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5)

Initial authorization duration: 2 years

REAUTHORIZATION CRITERIA Androgel®, generic transdermal testosterone products, Androderm®, Fortesta®, Natesto®, Testim®, Vogelxo®, Xyosted™, testosterone undecanoate (Jatenzo®, Tlando®, Kyzatrex®), methyltestosterone (Methitest®) is re-approved when there is documentation of positive clinical response to therapy.

Reauthorization duration: 2 years
 


 

Transdermal testosterone (Androgel®, Fortesta®, Testim®, Vogelxo®)

Secondary exposure: Virilization has been reported in children who were secondarily exposed to transdermal testosterone. Ensure that children avoid contact with unwashed or unclothed application sites in men using transdermal testosterone.  Advise patients to strictly adhere to recommended instructions for use.

Testosterone enanthate (Xyosted™) and testosterone undecanoate capsule (Jatenzo®, Tlando®, Kyzatrex®)

Blood pressure increase:

  • Xyosted™, Kyzatrex® and Jatenzo® can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.
  • Before initiating Xyosted™, Kyzatrex® and Jatenzo®, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of Xyosted™, Kyzatrex® and Jatenzo®  outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.
  • Due to this risk, use Xyosted™, Kyzatrex® and Jatenzo®  only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Androderm® (testosterone) [package insert]. Irvine, CA. Allergan USA, Inc. May 2020. Available from: https://www.allergan.com/assets/pdf/androderm_pi. Accessed NOVEMBER 20, 2023.

AndroGel® (testosterone) [package insert]. North Chicago, IL. AbbVie. May 2019. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8677ba5b-8374-46cb-854c-403972e9ddf3&type=displayAccessed NOVEMBER 20, 2023.

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59.

Fortesta® (testosterone) [package insert]. Malvern, PA. Endo Pharmaceuticals, Inc. June 2020. Available from: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=053a7300-0bce-11e0-9d16-0002a5d5c51b&type=display. Accessed NOVEMBER 20, 2023.

Gooren L . Hormone treatment of the adult transsexual patient. Horm Res. 2005;64(Suppl 2):31–36

Gooren LJG , Giltay EJ  . Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med . 2008;5(4):765–776.

Jatenzo® (testosterone undecanoate) capsules [prescribing information]. Northbrook, IL. Clarus Therapeutics, Inc. March 2019. Available from: https://www.jatenzo.com/assets/pdfs/jatenzo-pi.pdf. Accessed NOVEMBER 20, 2023.

Kaplan AL, Trinh QD, Sun M, Carter SC, Nguyen PL, Shih YC, Marks LS, Hu JC. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014 Apr;11(4):1063-70.

Kaufman J, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920-922.

Kyzatrex® (testosterone undecanoate) [prescribing information]. Raleigh, NC: Marius Pharmaceuticals LLC. September 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971. Accessed NOVEMBER 20, 2023.

Matsumoto AM. Diagnosis and evaluation of male hypogonadism. Medscape CME. 2008. Available from: http://www.medscape.org/viewarticle/575491. Accessed NOVEMBER 20, 2023.

Meriggiola MC , Gava G  . Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol (Oxf) . 2015;83(5):597–606.

Methitest® (methyltestosterone) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC.; October 2018. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561. Accessed NOVEMBER 20, 2023.

Meza J, Weaver K, Martin S. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer. Am Fam Physician. 2013 Oct 15;88(8):Online. Available from: http://www.aafp.org/afp/2013/1015/od5.pdf

Moore E , Wisniewski A , Dobs A  . Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab . 2003;88(8):3467–3473.

Natesto® (testosterone) [package insert]. Malvern, PA. Endo Pharmaceuticals, Inc. December 2017. Available from: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b0343bcc-7320-4bf2-bcb3-d95b6f4ba5fe&type=display. Accessed NOVEMBER 20, 2023.

Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, Miles BJ, Lipshults LI, Khera M. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013 Aug;190(2):639-44. Accessed NOVEMBER 20, 2023.

Seftel AD, Mack RJ, Secrest AR, et, al. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004; 25(6):963-972.

Steidle C, Schwartz S, Jacoby K, et, al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003; 88(6):2673-2681.

Testim® (testosterone) [package insert]. Malvern, PA. Auxilium Pharmaceuticals. April 2018. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9f2aae1f-898d-4955-be31-678e0cf85395&type=display. Accessed NOVEMBER 20, 2023.

Testosterone. Micromedex. Available from: http://www.micromedexsolutions.com. Accessed NOVEMBER 20, 2023.

Tlando® (testosterone undecanoate) [package insert]. Ewing, NJ. Antares Pharma Inc. March 2022. Available from: https://www.tlando.com/application/files/9416/5366/3764/TLANDO_PI__Medication_Guide__FINAL__032822.pdf#hcpisi. Accessed NOVEMBER 20, 2023.

Vogelxo® (testosterone) [package insert]. Maple Grove, MN.  Upsher-Smith Laboraories, Inc. April 2020. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2dd150f6-cdfd-4d51-8888-12b288f26262&type=display. Accessed NOVEMBER 20, 2023.

Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008 Nov;159(5):507-514.

Xyosted™ (testosterone enanthate) injection [package insert]. Ewing, NJ. Antares Pharma, Inc. November 2019. Available at: https://www.xyosted.com/PI.pdf. Accessed NOVEMBER 20, 2023.

The World Professional Association for Transgender Health. Standards of Care for the Heath of Transsexual, Transgender, and Gender Nonconforming People. 7th version. 2019. Available at: https://www.wpath.org/publications/soc. Accessed NOVEMBER 20, 2023.




249/14/20239/14/20241/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use
 


Brand NameGeneric Name
Androgel®Testosterone
Androderm®Testosterone
Fortesta®Testosterone
Natesto®Testosterone
Striant®Testosterone
Testim®Testosterone
Vogelxo®Testosterone
Jatenzo®, Tlando®, Kyzatrex®Testosterone undecanoate
Testred®, Android®, Methitest®Methyltestosterone
Xyosted™Testosterone enanthate

337
  
4/1/2024Rx.01.2CommercialOyenusi, OluwadamilolaQ4-2023

Age edits are used to ensure appropriate utilization in certain age groups.  An age edit may be placed on a medication when there are concerns for safe use or inappropriate utilization based on indication in a particular age group. Age edits may be based on the FDA approved label, available literature or accepted compendia as listed in the Off-Label Use Policy. When a medication listed below is prescribed to a member outside of the defined age range, the age edit will be applied and prior authorization will be required. 

Retinoids: adapelene (Differin®), tazarotene (Avage®, Tazorac®) and Tretinoin, topical (e.g. Atralin®, Avita®, Retin-A®, Retin A micro®, Altreno™, etc), triafarotene (Aklief®).

Topical retinoids may be used for cosmetic indications, including fine lines and wrinkles, in addition to treating acne.  Coverage of medications intended for cosmetic indications is an excluded benefit.  Studies of topical retinoids for fine lines and wrinkles included patients beginning in their 20s.  An age edit for members over the age of 25 years will be applied to ensure indication is not cosmetic.

Alzheimer medications:Donepezil (Aricept® [ODT]), Rivastigmine (Exelon®), Memantine (Namenda® [XR]), Galantamine (Razadyne® [ER]), Memantine/ donepezil (Namzaric®))

Studies for Alzheimer's disease were primarily conducted in patients over the age of 50 years.  An age edit will be applied to evaluate indication in members under the age of 50 years.

Oral liquids: Age edits may be applied to liquid dosage forms that have a tablet or capsule with the same indication to limit use to those under age 12 years.  Studies show that children as young as 6-11 years of age can be taught how to swallow solid dosage forms. 

Benign Prostate Hypertrophy (BPH); Dutasteride (Avodart®), Finasteride (Proscar®): Studies for BPH indicate this condition is most prevalent in men over the age of 50 years. An age edit will be applied to evaluate indication in members under the age of 50 years.


The intent of this policy is to communicate the medical necessity criteria for medications that have age edits as provided under the member’s prescription drug benefit.

The drugs in the following table are approved in the age ranges listed when there is documentation of all of the following:

  1. FDA or compendia approved indication; and
  2. Not used for an indication that is otherwise excluded (i.e., cosmetic); and
  3. Oral liquid dosage forms that have a tablet or capsule formulation available, one of the following:  
    1. Drug will be administered via nasogastric or gastronomy tube; or
    2. Member is unable to swallow an intact capsule or tablet

 

***Note: Age edits apply to brand and generic products.  Some brand name products have prior authorization in addition to age edit. 
Authorization Duration: 2 years 


Opioids (Butorphanol tartrate NS, Ultram®, Ultram ER®, Ultracet®, Conzip®, codeine containing products, hydrocodone containing cough and cold products)

  • Exposes patients and others to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors and conditions.  
  • Serious, life-threatening, or fatal respiratory depression may occur with use. Monitor for respiratory for respiratory depression, especially during initiation or following a dose increase.
  • Accidental exposure, especially by children, can result in fatal overdose.
  • Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatalogy experts.
  • Interactions with drugs affecting cytochrome P450 isoenzymes: the concomitant use of butorphanol tartrate NS with all cytochrome P450 3A4 inhibitors may result in an increase in butorphanol plasma concentrations, which could increase or prolong adverse reactions and potentially fatal respiratory depression. Discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in butorphanol concentration. The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol or codeine are complex and requires careful consideration of the effects on the parent drug and the active metabolite.  
  • Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Treximet® (sumatriptan/naproxen):

  • May cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Treximet® is contraindicated in the setting of coronary artery bypass graft.
  • NSAID containing products cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

ACE inhibitors (Epaned®, Qbrelis®):

  • Fetal toxicity. When pregnancy is detected discontinue Epaned®/Qbrelis® as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Benzodiazepines (Clobazem, Halcion®, Doral®, Restoril®, Ativan®, Onfi®, Oxazepam®, Tranxene®, Chlordiazepoxide, Estazolam, Flurazepam and Xanax®):

  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and duration to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.  
  • The use of benzodiazepines exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing benzodiazepine and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. 
  • Abrupt discontinuation or rapid dosage reduction of benzodiazepines after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue the benzodiazepine or reduce the dosage. 

Non-Steroidal Anti-Inflammatory Drugs (Naprosyn®, Indocin®)

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
  • Naprosyn® and Indocin® are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Nortriptyline

  • Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Nortriptyline hydrochloride is not approved for use in pediatric patients.

Xatmep™ (methotrexate oral solution):

  • Methotrexate can cause severe or fatal toxicities. Monitor closely and modify dose or discontinue for the following toxicities: bone marrow suppression, infection, renal, gastrointestinal, hepatic, pulmonary, hypersensitivity, and dermatologic. Methotrexate can cause embryo-fetal toxicity and fetal death. Use in polyarticular juvenile idiopathic arthritic arthritis is contraindicated in pregnancy. Consider the benefits and risks of Xatmep™ and risks to the fetus when prescribing Xatmep™ to a pregnant patient with a neoplastic disease. Advise patients to use effective contraception during and after treatment with Xatmep™.

Tegretol® (carbamazepine):

  • Serious and sometimes fatal dermatologic reactions, including Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), have been reported during treatment with Tegretol®. Studies in patients of Chinese ancestry have found a strong association between the risk of developing TEN/SJS and the presence of HLA-b*1502, an inherited allelic variant of the HLA-b gene. HLA-b*1502 is found almost exclusively in patients with ancestry across broad areas of Asia. Patients with ancestry in genetically at-risk populations should be screened for the presence of HLA-b*1502 prior to initiating treatment with Tegretol®. Patients testing positive for the allele should not be treated with Tegretol® unless the benefit clearly outweighs the risk.
  • Aplastic anemia and agranulocytosis have been reported in association with the use of Tegretol®. Data from a population-based case control study demonstrate that the risk of developing these reactions is 5-8 times greater than in the general population. However, the overall risk of these reactions in the untreated general population is low, approximately six patients per one million population per year for agranulocytosis and two patients per one million population per year for aplastic anemia. Although reports of transient or persistent decreased platelet or white blood cell counts are not uncommon in association with the use of Tegretol®, data are not available to estimate accurately their incidence or outcome. However, the vast majority of the cases of leukopenia have not progressed to the more serious conditions of aplastic anemia or agranulocytosis. Because of the very low incidence of agranulocytosis and aplastic anemia, the vast majority of minor hematologic changes observed in monitoring of patients on Tegretol® are unlikely to signal the occurrence of either abnormality. Nonetheless, complete pretreatment hematological testing should be obtained as a baseline. If a patient in the course of treatment exhibits low or decreased white blood cell or platelet counts, the patient should be monitored closely. Discontinuation of the drug should be considered if any evidence of significant bone marrow depression develops.

 

Riomet® [ER] (metformin):

  • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL.
  • Risk factors include renal impairment, concomitant use of certain drugs, age ≥ 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information.
  • If lactic acidosis is suspected, discontinue Riomet institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

 

Proazac® (fluoxetine)

  • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants.
  • Monitor for worsening and emergence of suicidal thoughts and behaviors.

Qdolo™ (tramadol)

  • Ensure accuracy when prescribing, dispensing, and administering QDOLO. Dosing errors due to confusion between mg and mL can result in accidental overdose and death
  • QDOLO exposes users to the risks of addiction, abuse and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing QDOLO, and monitor regularly for these behaviors or conditions.
  • To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products.
  • Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation or following a dose increase.
  • Accidental ingestion of QDOLO, especially by children, can result in a fatal overdose of tramadol.
  • Life-threatening respiratory depression and death have occurred in children who received tramadol. Some of the reported cases followed tonsillectomy and/or adenoidectomy; in at least one case, the child had evidence of being an ultra-rapid metabolizer of tramadol due to a CYP2D6 polymorphism
  • QDOLO is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (4). Avoid the use of QDOLO in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of tramadol.
  • Prolonged use of QDOLO, during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
  • The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with QDOLO requires careful consideration of the effects on the parent drug, tramadol, and the active metabolite, M1.
  • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.

Thyquidity™ (levothyroxine sodium)

  • Thyroid hormones, including THYQUIDITY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Valcyte® (valganciclovir)
 
  • Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with VALCYTE. 
  • Impairment of Fertility: Based on animal data and limited human data, VALCYTE may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females.
  • Fetal Toxicity: Based on animal data, VALCYTE has the potential to cause birth defects in humans.
  • Mutagenesis and Carcinogenesis: Based on animal data, VALCYTE has the potential to cause cancers in humans.​

Accolate® (zafirlukast) [prescribing information]. Wilmington, DE: Par Pharmaceuticals; December 2015. Accessed February 13, 2024
 
Aczone® (dapsone) [prescribing information]. Irvine, CA: Allergan; September 2019. https://www.almirall.us/pdf/aczone_7-5_pi_2019-09.pdf. Accessed February 13, 2024.
 
Adlarity® (donepezil transdermal system) [prescribing information]. Grand Rapids, MI: Corium Inc; March 2022. Available from: https://corium.com/products/ADLARITY/ADLARITY_PI_ENGLISH_US.pdf. Accessed February 13, 2024.
 
Aklief® (trifarotene) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P.: October 2019. Available at: https://www.galderma.com/us/sites/g/files/jcdfhc341/files/2019-10/10-2-2019%20Revised%20PI%20NDA%20211527.pdf. Accessed February 13, 2024.
 
Altreno™ (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceutical North America LLC. March 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1412aba5-71aa-4cce-8db4-c189bed1852c&type=display. Accessed February 13, 2024.
 
Atralin™ (tretinoin) [prescribing information]. Fort Worth, TX: Coria Laboratories, LTD.; July 2016. Revised July 2016. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b6b45969-a64a-4ce3-b3b6-157d2568a301&type=display Accessed February 13, 2024.
 
Amerge® (naratriptan HCl) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Revised October 2020. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13f4a8ec-75a3-4c51-b3bc-6244f3c79e95&type=display. Accessed February 13, 2024.
 
Arazlo™ (tazarotene) [prescribing information]. Quebec, Canada: Bausch Health Companies Inc. May 2021. Available at: https://www.bauschhealth.com/portals/25/pdf/pi/arazlo-pi.pdf. Accessed February 13, 2024.
 
Aricept® (donepezil) [prescribing information]. Teaneck, NJ: Pfizer, Inc.; November 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98e451e1-e4d7-4439-a675-c5457ba20975. Accessed February 13, 2024
 
Ativan ® (lorazepam) [prescribing information]. Eatontown, NJ: West-ward Pharmaceuticals; February 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017794s034s035lbl.pdf. Accessed February 13, 2024.

Atorvaliq® (atorvastatin calcium) [prescribing information]. Farmville, NC: CMP Pharma Inc. Feb 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213260s000lbl.pdf. Accessed February 13, 2024
 
Auvi-Q™ (epinephrine) [prescribing information]. Bridgewater, NJ. Sanofi-Aventis U.S. LLC. Revised September 2019. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6180fb40-7fca-4602-b3da-ce62b8cd2470&type=display Accessed February 13, 2024.
 
Avita® (tretinoin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals, Inc.; July 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302ca95f-5a7e-4971-870a-5cfea618d7a7 Accessed February 13, 2024.
 
Avodart® (dutasteride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2020. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avodart/pdf/AVODART-PI-PIL.PDF Accessed February 13, 2024.
 
Briviact® (brivaracetam) [prescribing information]. Smyrna, GA: UCB, Inc. March 2022. Available at: https://www.briviact.com/briviact-PI.pdf. Accessed February 13, 2024.
 
butorphanol tartrate [prescribing information]. Toronto, Ontario: Apotex Corp.; August 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404. Accessed February 13, 2024.
 
Casey, David A., et al. Drugs for Alzheimer's Disease: Are They Effective? U.S. National Library of Medicine, Apr. 2010, www.ncbi.nlm.nih.gov/pmc/articles/PMC2873716/. Accessed February 13, 2024.
 
Caverject® (alprostadil injection) [prescribing information]. New York, NY: Pfizer Inc. December 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a295fc1e-d82c-4f44-bc2d-a552bf594c98. Accessed February 13, 2024.
 
Doxycycline [prescribing information]. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b52e0a7-f024-4d8a-a59e-374946e60b44. Accessed November 25, 2020. Accessed February 13, 2024.
 
Edex® (alprostadil injection) [prescribing information]. Malvern, PA: Endo Pharmaceuticals, Inc. July 2018. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8b8ec8d-1318-43e4-a182-446e9f9579de. Accessed February 13, 2024.
 
Entadfi™ (finasteride and tadalafil) [prescribing information]. Miami, FL: ery Inc. December 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=112bf653-8322-4444-8d4d-03234b11c38c. Accessed December 28, 2022.
 
Firvanq® (vancomycin HCL) [prescribing information]. Wilmington, MA: Cutis Pharma; December 2021. Available at: https://firvanq.com/assets/pdf/FIRVANQ-PI-R1.pdf. Accessed February 13, 2024
 
Flolipid® (simvastatin suspension) [prescribing information]. Brooskville, FL: Salerno Pharmaceuticals LP. June 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ee17d10-6eb1-452a-99e8-02381368b3fe. Accessed February 13, 2024.
 
Furadantin® (nitrofurantoin suspension) [prescribing information]. Parsippany, NJ: Activis Pharma, Inc. December 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c5b015-626e-4d57-9b91-392fb53575fa. Accessed February 13, 2024.
 
Hillebrand, G.G., et al. “New Wrinkles on Wrinkling: an 8‐Year Longitudinal Study on the Progression of Expression Lines into Persistent Wrinkles." British Journal of Dermatology, Wiley/Blackwell (10.1111), 22 Feb. 2010, onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2133.2010.09709.x. Accessed February 13, 2024.
 
Hycodan® (hydrocodone bitartrate and homatropine methylpromide) [prescribing information]. Allentown, PA: Genus Lifesciences Inc.; December 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78. Accessed February 13, 2024
 
Imitrex® (sumatriptan succinate) [prescribing information]. Canada: GlaxoSmithKiline LLC. December 2020. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32f6d89b-4aea-5396-e054-00144ff88e88. Accessed February 13, 2024.
 
Indocin® (indomethacin suspension) [prescribing information]. Wayne, PA: Zyla Life Sciences US Inc. April 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73878376-1d24-423b-9f37-3666e83c95da. Accessed February 13, 2024
 
Katerzia® (amlodipine suspension) [prescribing information]. Greenwood Village, CO, Silvergate Pharmaceuticals Inc. October 2020. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=df673a4d-acb8-444c-a472-c87ab8cbd366&type=display. Accessed February 13, 2024.
 
Luebberding, Stefanie, et al. Quantification of Age-Related Facial Wrinkles in Men and... : Dermatologic Surgery. Oxford University Press, 2014, journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2014&issue=01000&article=00003&type=abstract.  February 13, 2024
 
Lyrica® (pregabalin) oral solution [prescribing information]. New York, NJ: Pfizer. June 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60185c88-ecfd-46f9-adb9-b97c6b00a553.. Accessed February 13, 2024
 
Maxalt® (rizatriptan benzoate) [prescribing information]. Whitehouse Station, NJ: Merck& Co., Inc.; 2012. Revised June 2021.  https://www.merck.com/product/usa/pi_circulars/m/maxalt/maxalt_pi.pdf Accessed February 13, 2024.
 
Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr. 2006;45:725-33. Accessed February 13, 2024
 
Mestinon® (pyridostigmine bromide) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC. December 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a851795e-b7a8-40c3-9922-5e79d3eb4d92. Accessed February 13, 2024.
 
Muse® (alprostadil urethral suppository) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals. April 2018. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55f3f9-c4cf-11df-851a-0800200c9a66. Accessed July 21, 2021.
 
Namenda® (memantine HCl) [prescribing information]. St. Louis, MO: Forest Laboratories, Inc.; 2012. Revised November 2018.  https://www.allergan.com/assets/pdf/namenda_pi Accessed February 13, 2024.
 
Namzaric™ (Memantine/ donepezil) [prescribing information]. St. Louis, MO: Forest Laboratories, Inc.; January 2019. https://www.allergan.com/assets/pdf/namzaric_pi Accessed February 13, 2024.
 
Naprosyn® (naproxen) [prescribing information]. Athens, GA: Athena Bioscience. August 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b4173d-7836-4d7d-b149-1d96f9377ad0. February 13, 2024.
 
Neurontin® (gabapentin) [prescribing information]. New York, NY: Parke-Davis, Division of Pfizer Inc. April 2020. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=630. Accessed February 13, 2024.
 
Norliqva® (amlodipine) [prescribing information]. Farmville, NC: CMP Pharma Inc; February 2022. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1730a51-4383-4c61-a9a1-7e1326bd0abe. Accessed February 13, 2024.
 
Nortriptyline [prescribing information]. Greensville, SC: Pharmaceutical Associates, Inc. February 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fcabf90-357a-4a06-b680-9572dc28bcfe. Accessed February 13, 2024.
 
Nurtec® ODT (rimegepant) [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals, Inc.; April 2022. Available from: https://www.nurtec.com/pi. Accessed February 13, 2024.
 
Onfi® (clobazam) [prescribing information]. Winchester, KY: Catalent Pharma Solutions, LLC. February 2021. Available at: https://www.lundbeck.com/upload/us/files/pdf/Products/ONFI_PI_US_EN.pdf. Accessed February 13, 2024.
 
Oxazepam [prescribing information]. Princeton, NJ: Sandoz Inc.; 2011. Revised February 2021. Accessed February 13, 2024.
 
Proscar® (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; June 2021.  Accessed February 13, 2024.
 
“Prostate Enlargement (Benign Prostatic Hyperplasia)." National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Department of Health and Human Services, 1 Sept. 2014, www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostate-enlargement-benign-prostatic-hyperplasia.
 
Prozac® (fluoxetine) oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc. December 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=180a07fd-1f6a-4617-b8e0-f938c65ba273. Accessed February 13, 2024.
 
Qbrelis® (lisinopril) [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals; July 2020. Available from: https://qbrelis.com/Qbrelis-Prescribing-Info.pdf. Accessed February 13, 2024.
 
Qdolo™ (tramadol) [prescribing information]. Athens, GA: Athena Bioscience, LLC. September 2020. Available at: https://qdolo.com/wp-content/uploads/2020/10/QDOLO-Prescribing-Information.pdf. Accessed February 13, 2024.
 
Qiu, Chengxuan, et al. Epidemiology of Alzheimer's Disease: Occurrence, Determinants, and Strategies toward Intervention. U.S. National Library of Medicine, June 2009, www.ncbi.nlm.nih.gov/pmc/articles/PMC3181909/. Accessed February 13, 2024.
 
Razadyne ER ® (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2016. Revised October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021169s033,021615s024lbl.pdf. Accessed February 13, 2024.
 
Relenza® (zanamivir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2012. Revised October 2021. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Relenza/pdf/RELENZA-PI-PIL-COMBINED.PDF. Accessed February 13, 2024.
 
Relpax® (eletriptan) [prescribing information]. New York, NY: Roerig (Pfizer Inc.); 2012. Revised March 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=621 Accessed February 13, 2024.
 
Restoril™ (Temazepam) [prescribing information]. Webster Groves, MO: Mallinckrodt; 2016. Revised February 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018163s065lbl.pdf. Accessed February 13, 2024.
 
Retin-A® (tretinoin) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America; 2016. Revised September 2019. Accessed February 13, 2024.
 
Retin-A Micro® (tretinoin) [prescribing information].  Bridgewater, NJ: Valeant Pharmaceuticals North America; 2016. Revised October 2017. Accessed February 13, 2024.
 
Reyvow® (lasmiditan) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; September 2022. Available from: http://pi.lilly.com/us/reyvow-uspi.pdf. Accessed February 13, 2024.
 
Riomet® (metformin hydrochloride) oral solution [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; November 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021591s007lbl.pdf. Accessed February 13, 2024.
 
Riomet ER™ (metformin hydrochloride for extended-release oral suspension) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; August 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212595s000lbl.pdf. Accessed February 13, 2024.
 
Tegretol® (carbamazepine) [prescribing information]. East Hanover, NJ: Norvatis Pharmaceuticals Corporations. March 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d409411-aa9f-4f3a-a52c-fbcb0c3ec053. Accessed  February 13, 2024
 
Thyquidity™ (levothyroxine sodium) oral solution [prescribing information]. Largo, FL: Vertice Specialty Group. December 2020. Available at: https://www.thyquidity.com/pdf/Prescribing-Information.pdf. Accessed February 13, 2024
 
Tosymra (sumatriptan) nasal spray [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC. February 2021. Available from: www.upsher-smith.com/wp-content/uploads/TOS-MI.pdf. Accessed February 13, 2024.
 
Tranxene® (clorazepate) [prescribing information]. Lebanon, NJ: AbbVie LTD; May 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017105s079lbl.pdf. Accessed February 13, 2024.
 
Treximet® (sumatriptan/naproxen) [prescribing information]. Morristown, NJ. Pernix Therapeutics. April 2021. http://www.treximet.com/Areas/Patient/Contents/pdf/prescribing-information.pdf Accessed February 13, 2024
 
Trileptal® (oxcarbazepine) oral suspension. [prescribing information] East Hanover, NJ: Norvatis. May 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b. Accessed February 13, 2024.
 
Twyneo® (Tretinoin-benzoyl peroxide) [prescribing information]. Fort Worth, TX: Galderma Laboratories, L.P. July 2021. Available from: https://www.galderma.com/us/sites/default/files/2022-02/Twyneo_PI.pdf. Accessed February 13, 2024.
 
Ubrelvy® (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA, Inc; March 2021. https://media.allergan.com/products/Ubrelvy_pi.pdf. Accessed February 13, 2024
 
Ultracet® (tramadol/acetaminophen) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; April 2022. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ULTRACET-pi.pdf. Accessed February 13, 2024
 
Ultram® (tramadol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; October 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021692s015lbl.pdf Accessed February 13, 2024
 
Ultram® ER (tramadol ER) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; September 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021692s015lbl.pdf. Accessed February 13, 2024.
 
Valganciclovir (Valcyte) [prescribing information]. San Francisco, CA: Genetech USA, inc. December 2021. VALCYTE Prescribing Information (gene.com). Accessed November 4, 2022. 
 
Xanax® (alprazolam) [prescribing information]. New York, NY: Pharmacia & Upjohn Company; March 2021. http://labeling.pfizer.com/ShowLabeling.aspx?id=547 Accessed February 13, 2024.
 
Xatmep™ (methotrexate) [prescribing information]. Greenwood Village, CO: Silvergate Pharmaceuticals, Inc.; September 2020. https://xatmep.com/Xatmep-Prescribing-Info.pdf. Accessed February 13, 2024.
 
Zavzpret™ (zavegepant) [package insert]. New York, NY: Pfizer Inc. March 2023. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=19471. Accessed February 13, 2024
 
Ziana® (tretinoin/clindamycin) [prescribing information]. Brigewater, NJ: Medicis Pharmaceutical Corp; Revised March 2017. Accessed February 13, 2024.
 
Zomig® (zolmitriptan) [prescribing information]. Macclesfield, Cheshire UK: AstraZeneca Pharmaceuticals; 2012. Revised May 2019.  Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=84b51cb9-83f3-4a49-7fa3-1adc0f963658&type=display. Accessed February 13, 2024.
 
Zomig NS® (zolmitriptan nasal) [prescribing information]. Macclesfield, Cheshire UK: AstraZeneca Pharmaceuticals; 2012. Revised April 2019. https://www.azpicentral.com/zomig_nasal/zomig_nasal.pdf#page=1. Accessed February 13, 2024.
 
Zyflo CR® (Zileuton) [prescribing information]. Cary, NC: Chiesi USA, Inc., Revised December 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022052s014lbl.pdf. Accessed February 13, 2024.

3612/18/202312/18/20244/1/2024 1:22 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off Label Use

Rx.01.17 Cosmetic Policy

Rx.01.251 Migraine and Headache agents

Rx.01.197 Opioid Policy

Rx.01.202 Prior authorization requirements for select drugs

Rx.01.33 Off-Label Use

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit​



Drug NameAge Edit:  Prior Authorization Required (years)
Acne Medications
Tretinoin, topical (e.g., Atralin, Avita, Retin-A, Retin-A micro, Altreno, etc.)Age 26 and over
Adapalene (Differin)Age 26 and over
Adapalene/ Benzoyl Peroxide (Epiduo)Age 26 and over
Tretinoin/ clindamycin (Ziana)Age 26 and over
Dapsone (Aczone) 5%Under age 12
Dapsone (Aczone) 7.5%Under age 9
Triafarotene (Aklief)Age 26 and over
Tazarotene (Fabior, Arazlo, Tazorac)Age 26 and over
Tretinoin-benzoyl peroxide (Twyneo)Age 26 and over
Alzheimer's Drugs
Donepezil (Aricept [ODT]), AdlarityUnder age 50
Rivastigmine (Exelon)Under age 50
Memantine (Namenda [XR])Under age 50
Galantamine (Razadyne [ER])Under age 50
Memantine/ donepezil (Namzaric)Under age 50
Anticonvulsant Agents
Clobazam (Onfi) suspension Age 13 and over
Rufinamide (Banzel) suspension Age 13 and over
Carbamazepine (Tegretol) suspension Age 13 and over
Gabapentin (Neurontin) Oral solution Age 13 and over
Brivaracetam (Briviact) oral solution Age 13 and over
Pregabalin solution (Lyrica®)Age 13 and over
Oxcarbazepine suspension (Trileptal®)Age 13 and over
Antidepressants
Nortriptyline solutionAge 13 and over
Fluoxetine solution (Prozac)Age 13 and over
Antidiabetic Agents
Metformin (Riomet) ER solutionAge 13 and over
Metformin (Riomet) suspension                                      Age 13 and over
Acute migraine Agents
Eletriptan (Relpax)Under age 18
Sumatriptan (Imitrex, Onzetra. Xsail, Zembrace Symtouch, Tosymra)Under age 18
Butorphanol tartrate NSUnder age 18
Naratriptan (Amerge)Under age 18
Rizatriptan (Maxalt/ Maxalt MLT)Under age 6
Zolmitriptan (Zomig/Zomig ZMT)Under age 12
Almotriptan    Under age 12
Frovatriptan (Frova)Under age 18
Sumatriptan/naproxen (Treximet)Under age 12
TosymraUnder age 18
Lasmiditan (Reyvow)Under age 18
Ubrogepan (Ubrelvy)Under age 18
Rimegepant (Nurtec ODT)Under age 18
Zavegepant (Zayzpret)Under age 18
Antihypertensives
Amlodipine (Katerzia, Norliqva)Age 13 and over
Enalapril (Epaned)Age 13 and over
Lisinopril (Qbrelis)Age 13 and over
Valsartan oral solutionAge 13 and over
Anti-Infectives
Vancomycin oral solution (Firvanq)Age 13 and over
Zanamivir (Relenza)Under age 5
Nitrofurantoin suspension (Furdantin)Age 13 and over
Doxycycline hyclate DR 75mg, 150mg (Doryx 75mg, 150mg), Doxycycline hyclate 75mg, 150mg (Acticlate 75mg, 150mg), Doxycycline monohydrate /Mondoxyn NL 75mg capsule (Monodox 75mg), Doxycycline monohydrate 150mg capsule and tablet (Adoxa 150mg)Age 18 and over
Valganciclovir oral solution (Valcyte)Age 13 and over
Benign Prostate Hypertrophy
Dutasteride (Avodart)Under age 50
Finasteride (Proscar)Under age 50
Finasteride-Tadalafil (Entadfi)Under age 50
Erectile Dysfunction Agents
Alprostadil (Muse®, Edex®, Caverject®, IFE-PG20)Under age 55
Benzodiazepines
FlurazepamUnder age 15
Triazolam (Halcion)Under age 18
Quazepam (Doral)Under age 18
EstazolamUnder age 18
Temazepam (Restoril)Under age 18
Lorazepam (Ativan)Under age 12
ChlordiazepoxideUnder age 6
OxazepamUnder age12
Clorazepate (Tranxene)Under age 9
Alprazolam (Xanax) Under age 18
Leukotriene Inhibitors
Zafirlukast (Accolate)Under age 5
Zileuton (Zyflo [CR])Under age 12
Pain

Tramadol/Tramadol ER containing products

(e.g., Ultram, Ultram ER, Ultracet, Conzip) 

Under age 12
Tramadol solution (Qdolo)Under age 18
Codeine containing productsUnder age 12
Indomethacin (Indocin) suspensionAge 13 and over
Naproxen (Naprosyn) suspensionAge 13 and over
Cough/Cold Products
Codeine and hydrocodone containing productsUnder age 18
Miscellaneous
Auvi-Q 0.1mgAge 4 and over
Xatmep (Methotrexate solution)      Age 13 and over
Pyridostigmine (Mestinon) solutionAge 13 and over
Thyquidity solutionAge 13 and over
Simvastatin (Flolipid) suspensionAge 13 and over
Atorvastatin calcium suspension (Atorvaliq)Age 13 and over

 



medications that have age edits medications that have age edits
338
  
4/1/2024Rx.01.259CommercialOyenusi, OluwadamilolaQ4-2023

The antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These vasculitis are complex, immune-mediated disorders in which tissue injury results from the interplay of an initiating inflammatory event and a highly specific immune response. Part of this response is directed against previously shielded epitopes of neutrophil granule proteins, leading to high-titer autoantibodies known as ANCA. The production of ANCA is one of the hallmarks of the ANCA-associated vasculitis. ANCA are directed against antigens present primarily within the granules of neutrophils and monocytes; these autoantibodies produce tissue damage via interactions with primed neutrophils and endothelial cells.

Avacopan (Tavneos™) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. Avacopan does not eliminate glucocorticoid use.

Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration. The precise mechanism by which avacopan exerts a therapeutic effect in patients with ANCA-associated vasculitis has not been definitively established.



The intent of this policy is to communicate the medical necessity criteria for Avacopan (Tavneos™) as provided under the member's prescription drug benefit. 

INITIAL CRITERIA: Avacopan (Tavneos™) is approved when ALL of the following are met:

  1. Diagnosis of one of the following types of severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis:
    1. Granulomatosis with polyangiitis (GPA); or
    2. Microscopic polyangiitis (MPA); and
  2. Member is receiving concurrent immunosuppressant therapy with one of the following:
    1. Cyclophosphamide; or
    2. Rituximab; and
  3. One of the following:
    1. Member is concurrently on glucocorticoids (e.g., prednisone); or
    2. Inadequate response or inability to tolerate glucocorticoids (e.g., prednisone); and
  4. Member is 18 years of age or older; and
  5. Prescribed by or in consultation with one of the following:
    1. Nephrologist; or
    2. Pulmonologist; or
    3. Rheumatologist


Initial authorization duration: 6 months

REAUTHORIZATION CRITERIA: Avacopan (Tavneos™) is re-approved when ALL of the following are met:

  1. Member does not show evidence of progressive disease while on therapy; and
  2. Member is receiving concurrent immunosuppressant therapy (e.g., azathioprine, cyclophosphamide, methotrexate, rituximab); and
  3. Prescribed by or in consultation with one of the following:
    1. Nephrologist; or
    2. Pulmonologist; or
    3. Rheumatologist


Reauthorization duration: 2 years
 


None

Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. UpToDate. October 2020. Available at: https://www.uptodate.com/contents/pathogenesis-of-antineutrophil-cytoplasmic-autoantibody-associated-vasculitis?search=antineutrophil%20cytoplasmic%20autoantibody%20associated%20vasculitis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed February 13, 2024

Tavneos (avacopan) [package insert]. Cincinnati, OH. ChemoCentryx, Inc. Feburary 2022. Available at:

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0&type=displayAccessed February 13, 2024


312/18/202312/18/20244/1/2024 1:22 AMNo presence informationsrv_ppsgw_P
​Rx.01.33 Off Label Use
Tavneos™Avacopan
245
  
10/1/2023Rx.01.6CommercialOyenusi, Oluwadamilola

Aztreonam (Cayston®) is a monobactam antibiotic, which is part of the beta-lactam class, that binds to penicillin binding proteins of susceptible bacteria and leads to inhibition of bacterial cell wall synthesis and death of the cell.

Aztreonam (Cayston®) is indicated to improve respiratory symptoms in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infections. Safety and effectiveness has not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.


 

The intent of this policy is to communicate the medical necessity criteria for aztreonam (Cayston®) as provided under the member’s prescription drug benefit.


 

INITIAL CRITERIA: Aztreonam (Cayston®) is approved when ALL of the following are met:

  1. Member is 7 years of age or older; AND
  2. Diagnosis of cystic fibrosis; AND
  3. Evidence of Pseudomonas aeruginosa in the lungs confirmed by culture; AND
  4. Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam; AND
  5. FEV1 that is 25% to 75% of predicted

Initial authorization duration: 2 years

REAUTHORIZATION CRITERIA: Aztreonam (Cayston®) is re-approved when ALL of the following are met:

  1. Diagnosis of cystic fibrosis; AND
  2. Evidence of Pseudomonas aeruginosa in the lungs confirmed by culture; AND
  3. Documentation of positive clinical response to therapy (e.g. improvement in lung function demonstrated by improved FEV1)

Reauthorization duration: 2 years


N/A

Cayston® [package insert]. Foster City CA. Gilead Sciences. November 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=67300ca3-8c53-4ce4-8e86-2c03be1f9b8a&type=display.  Accessed June 22, 2023.  

McCoy K, Quittner A, Oermann C, et al. Inhaled Aztreonam Lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care 2008; 178(9): 921-928. Accessed June 22, 2023. 

Oermann C, Retsch-Bogart G, Quittner A, et al. An 18 month study of the safety and efficacy of repeated courses of inhaled Aztreonam Lysine in Cystic Fibosis. Pediatric Pulmonology2010; 45(11): 1121-1134. Accessed June 22, 2023.

Retsch-Bogart G, Quittner A, Gibson R, et al. Efficacy and Safety of inhaled Aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135(5): 1223-1232.  Accessed June 22, 2023.​



 


 


 

156/8/20236/8/202410/1/2023 1:23 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use
 


Brand Name Generic Name
Cayston® Aztreonam

384
  
7/1/2024Rx.01.225CommercialOyenusi, OluwadamilolaQ1-2024

Diabetic foot ulcers are a prevalent complication of diabetes mellitus and represent major causes of morbidity and mortality. 15% of all diabetic individuals are affected by foot ulcers during their lifetime and 15-20% of those patients go on to need an amputation. Risk factors for development of diabetic foot ulcers include neuropathy, peripheral vascular disease, and poor glycemic control. Peripheral neuropathy results in patient loss of sensation and can exacerbate the development of ulcerations. Peripheral vascular disease can lead foot tissues to become ischemic. Many wounds go unnoticed and worsen through repetitive pressure because patients are unable to detect trauma to their lower extremities.  Multidisciplinary treatment today includes: surgical debridement, dressings promoting a moist wound environment, wound off-loading, vascular assessment, treatment of active infection, and glycemic control.

Regranex® gel is a recombinant human platelet-derived growth factor that promotes cellular proliferation and angiogenesis and thereby improve ulcer healing. Regranex® gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. Regranex® gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices.


The intent of this policy is to communicate the medical necessity criteria for becaplermin (Regranex®) gel as provided under the member's prescription drug benefit.

INITIAL CRITERIA: Becaplermin (Regranex®) gel is approved when BOTH of the following are met:

  1. Member has a lower extremity diabetic neuropathic ulcer; and
  2. Treatment will be given in combination with ulcer wound care (e.g., debridement, infection control, and/or pressure relief)

Initial authorization duration: 6 months

REAUTHORIZATION CRITERIA: Becaplermin (Regranex®) gel is re-approved when ONE of the following is met:

  1. Documentation of lower extremity diabetic neuropathic ulcer at a different treatment site; or
  2. Documentation of continued need for treatment beyond 6 months

Reauthorization duration: 6 months


None

Pendsey, S. Understanding diabetic foot. Int J Diabetes Dev Ctries 2010; 30:75-9. Accessed April 17, 2024.

Armstrong, D., J de Asla, R. Management of diabetic foot ulcers. UpToDate. March 2023. Available from: https://www.uptodate.com/contents/management-of-diabetic-foot-ulcers?search=diabetic%20foot%20ulcer&source=search_result&selectedTitle=1~61&usage_type=default&display_rank=1. Accessed April 17, 2024.

Regranex® (becaplermin gel) [prescribing information]. Fort Worth, TX: Smith & Nephew, Inc. December 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd2c7d21-7b07-4ab3-8983-816ab3223771. Accessed April 17, 2024.


53/14/20243/14/20257/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off Label Use 
Brand nameGeneric name
Regranex®Becaplermin

NANA
385
  
7/1/2024Rx.01.203CommercialOyenusi, OluwadamilolaQ1-2024

Systemic lupus erythematosus (SLE) is an autoimmune disorder that is very heterogeneous with respect to its severity and the organs affected. Approximately 1.5 million Americans, primarily women of childbearing age, have a form of lupus. SLE represents approximately 70% of all lupus cases. Common clinical manifestations of SLE include pain, extreme fatigue, hair loss, cognitive issues, rashes (often the classic “butterfly rash”), arthritis and arthralgias. More severe clinical manifestations include renal, hematologic, or central nervous system involvement. SLE is often associated with relapses (which can be acute or chronic) and remissions.

Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe organ manifestation of systemic lupus erythematosus (SLE). Most patients with SLE who develop LN do so within 5 years of an SLE diagnosis and in many cases, LN is the presenting manifestation resulting in the diagnosis of SLE. Treatment of LN usually involves immunosuppressive therapy, typically with mycophenolate mofetil or cyclophosphamide and with glucocorticoids, although these treatments are not uniformly effective. Within 10 years of an initial SLE diagnosis, 5 to 20% of patients with LN develop end-stage kidney disease.   

BLyS, a B-cell survival factor, is overexpressed in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.  Belimumab is an inhibitor that targets B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells by blocking the binding of BLyS to its receptors on B-cells. An intravenous (IV) formulation of belimumab was approved by the FDA in 2011.

A subcutaneous formulation of the medication was approved by the FDA in July 2017. 

Benlysta® (belimumab) is indicated for the treatment of:

  • Patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
  • Patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.
  • Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations.

Voclosporin is a calcineurin-inhibitor immunosuppressant. Activation of lymphocytes involve an increase in intracellular calcium concentrations that bind to the calcineurin regulatory site and activate calmodulin binding catalytic subunit and through dephosphorylation, activates the transcription factor Nuclear Factor of Activated T-Cell Cytoplasmic (NFATc). The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens.

Lupkynis™ (voclosporin) is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis

The intent of this policy is to communicate the medical necessity criteria for belimumab (Benlysta®) and voclosporin (Lupkynis™) as provided under the member's prescription drug benefit.

Systemic Lupus Erythematosus 
INITIAL CRITERIA Belimumab (Benlysta®) is approved when ALL of the following are met:

  1. Diagnosis of active systemic lupus erythematosus; and
  2. Autoantibody positive (ie, anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL), antibodies to DNA [Anti-dsDNA], Anti-Smith [Anti-Sm]); and
  3. Currently receiving at least one standard of care treatment for active systemic lupus erythematosus (eg, antimalarials [eg, hydroxychloroquine], corticosteroids, NSAIDs, or immunosuppressants); and
  4. Prescribed by or in consultation with a rheumatologist; and
  5. Member is 5 years of age or older

 
Initial Authorization duration: 6 months

REAUTHORIZATION CRITERIA: Belimumab (Benlysta®) is re-approved when there is documentation of positive clinical response to therapy.

Reauthorization duration: 2 years

Lupus Nephritis
INITIAL CRITERIA Belimumab (Benlysta®) is approved when ALL of the following are met:

  1. Member has active lupus nephritis confirmed by kidney biopsy; and
  2. Member is receiving standard therapy for lupus nephritis (e.g. corticosteroids, immunosuppressants, azathioprine); and
  3. Prescribed by or in consultation with a rheumatologist or nephrologist; and
  1. Member is 5 years of age or older


INITIAL CRITERIA Voclosporin (Lupkynis™) is approved when ALL of the following are met:

  1. Diagnosis of active lupus nephritis; and
  2. Member is 18 years of age or older; and
  3. Used in combination with mycophenolate mofetil and corticosteroids; and
  4. Prescribed by or in consultation with nephrologist or rheumatologist 

 
Initial Authorization duration: 6 months

REAUTHORIZATION CRITERIA: Belimumab (Benlysta®) or Voclosporin (Lupkynis™) is re-approved when there is documentation of positive clinical response to therapy.
 

Reauthorization duration: 2 years 


Lupkynis™ (Voclosporin)
Malignancies and serious infections: Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death.

Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9. PMID: 31974366. Accessed April 17, 2024.

Benlysta® [Package Insert]. Rockville, MD: Human Genome Sciences, Inc.; February 2023. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2fa3c528-1777-4628-8a55-a69dae2381a3&type=display. Accessed April 17, 2024.

Gladman DD, Pisetski DS, Curtis MR. Clinical manifestations of systemic lupus erythematosus in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www-uptodate-com.proxy1.lib.tju.edu/contents/overview-of-the-clinical-manifestations-of-systemic-lupus-erythematosus-in-adults?source=search_result&search=lupus&selectedTitle=1~150. Accessed on April 17, 2024.

Lupus facts and statistics. Lupus Foundation of America Web Site. https://resources.lupus.org/entry/facts-and-statistics. Published 2017. Accessed April 17, 2024.

Lupkynis™ (voclosporin) [prescribing information]. Rockville, MD: Aurinia Pharma U.S., Inc.; January 2021. Available from: https://d1io3yog0oux5.cloudfront.net/auriniapharma/files/pages/lupkynis-prescribing-information/FPI-0011+Approved+USPI++MG.pdf. Accessed April 17, 2024.


103/14/20243/14/20257/1/2024 1:23 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off-Label Use

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit


Brand NameGeneric Name
Benlysta®belimumab
Lupkynis™voclosporin

NANA
328
  
1/1/2024Rx.01.256CommercialOyenusi, Oluwadamilola

Graft-versus-host disease (GVHD) can develop after allogeneic hematopoietic cell transplant (HCT), when immune cells from a non-identical donor (the graft) initiate an immune reaction against a transplant recipient (the host). Chronic GVHD is a syndrome of variable clinical features that resembles autoimmune and other immunologic disorders (eg, scleroderma, Sjögren's syndrome, primary biliary cirrhosis, bronchiolitis obliterans). Clinical manifestations may be widespread, or they may be restricted to a single organ or site. The primary clinical manifestations are skin involvement (resembling lichen planus or cutaneous scleroderma), dry oral mucosa, gastrointestinal tract ulcerations and sclerosis, elevated serum bilirubin, and bronchiolitis obliterans. Chronic GVHD is a major cause of morbidity and mortality after allogeneic HCT, which worsen with increasing disease severity. Patients have impaired physical, social, and psychological well-being and impaired quality of life.

 

Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK2 and ROCK1 with IC50 values of approximately 100 nM and 3 μM, respectively. Belumosudil down- regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro-human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro. In vivo, belumosudil demonstrated activity in animal models of chronic GVHD.

 

REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

The intent of this policy is to communicate the medical necessity criteria for Belumosudil (Rezurock™) as provided under the member's prescription drug benefit.

INITIAL CRITERIA Belumosudil (Rezurock™) is approved when ALL of the following are met:

  1. Diagnosis of chronic graft-versus-host disease; and
  2. Member is 12 years of age or older; and
  3. Inadequate response or inability to tolerate two or more lines of systemic therapy (e.g., corticosteroids, mycophenolate, etc.); and
  4. Prescribed by or in consultation with one of the following:
    1. Hematologist; or
    2. Oncologist; or
    3. Physician experienced in the management of transplant patients

Initial authorization duration: 2 years

REAUTHORIZATION CRITERIA Belumosudil (Rezurock™) is re-approved if member does not show evidence of progressive disease while on therapy

Reauthorization duration: 2 years

 

​N/A

Rezurock™ [package insert]. Warrendale, PA: Kadmon Pharmaceuticals. April 2023. Available at: https://www.rezurock.com/full-prescribing-information.pdf. Accessed October 02, 2023.

Zeiser R. Clinical manifestations and diagnosis of chronic graft-versus-host disease. UpToDate website. Last updated February 17, 2022. Available at http://www.uptodate.com/. Accessed October 02, 2023.​





39/14/20239/14/20241/1/2024 1:28 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off Label Use

Brand NameGeneric Name
RezurockTMBelumosudil
262
  
10/1/2023Rx.01.208CommercialOyenusi, Oluwadamilola

Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP.

Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection. The pathophysiology is multifactorial and includes direct bone marrow suppression, an overactive spleen, decreased production of thrombopoietin and therapeutic adverse effect all contributing to thrombocytopenia.

Aplastic Anemia: A blood disorder caused by failure of the bone marrow to make enough new blood cells. Bone marrow is a sponge-like tissue inside the bones that makes stem cells that differentiate into red blood cells, white blood cells, and platelets.

Thrombocytopenia in patients with chronic liver disease: Individuals with chronic liver disease have varying degree of thrombocytopenia which may be caused by impaired platelet production from decreased hepatic synthesis of thrombopoietin. In addition, individuals with advanced liver disease may have reduced platelet function due to coexisting uremia, infection, and/or endothelial abnormalities. These factors combined put the individuals with chronic liver disease at an increased risk for bleeding especially during procedures.

Mechanism of Action:

Eltrombopag olamine (Promacta®) tablets contain a thrombopoietin (TPO) receptor agonist for oral administration. Eltrombopag interacts with the transmembrane domain of the TPO receptor which initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells ultimately increasing platelet production. 

Eltrombopag olamine (Promacta®) is a thrombopoietin receptor agonist indicated for the treatment of:

  1. Thrombocytopenia in adult and pediatric patients 1 year and older with chronic idiopathic thrombocytopenia purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. 
  2. Thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should only be used in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. 
  3. In combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
  4. Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Fostamatinib disodium (Tavalisse) is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). The major metabolite of fostamatinib, R406, inhibits signal transduction of Fc-activating receptors and B-cell receptor. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.

Fostamatinib disodium (Tavalisse) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Avatrombopag (Doptelet®) and lusutrombopag (Mupleta®) tablets contain a thrombopoietin (TPO) receptor agonist for oral administration. They stimulate proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Lusutrombopag induces megakaryocyte maturation by interacting with the transmembrane domain of human TPO receptor expressed on megakaryocytes.

Avatrombopag (Doptelet®) and Lusutrombopag (Mupleta®)are indicated for the treatment of thrombocytopenia in adult patients  with chronic liver disease who are scheduled to undergo a procedure. ​

Doptelet® (avatrombopag) is also indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

​The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit.

Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

INITIAL CRITERIA: Eltrombopag olamine (Promacta®) is approved when ALL of the following are met:

  1. Diagnosis of relapsed/refractory chronic immune (idiopathic) thrombocytopenic purpura (ITP) for greater than 6 months; and
  2. Member is 1 year of age or older; and
  3. Baseline platelet count is less than 30,000/mcL; and
  4. Insufficient response to corticosteroids, immunoglobulins, or splenectomy; and
  5. Prescribed by or in consultation with a hematologist/oncologist​

Initial authorization duration: 2 years

INITIAL CRITERIA: Fostamatinib (Tavalisse™) is approved when all of the following are met:

  1. Diagnosis of chronic immune (idiopathic) thrombocytopenic purpura; and
  2. Baseline platelet count is less than 30,000/mcL; and
  3. Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding; and
  4. Documentation of an inadequate response or inability to tolerate ONE of the following:
    1. Corticosteroids; or 
    2. Immunoglobulins; or
    3. Splenectomy; or
    4. Thrombopoietin receptor agonists (e.g., Nplate®, Promacta®); or
    5. Rituximab; and
  5. Prescribed by or in consultation with a hematologist/oncologist; and
  6. Member is 18 years of age or older

Initial authorization duration: 2 years

INITIAL CRITERIA: Avatrombopag (Doptelet®) is approved when ALL of the following are met:

  1. Diagnosis of Chronic Immune Thrombocytopenia (ITP) or relapsed/refractory ITP; and
  2. Baseline platelet count is less than 30,000mcL; and
  3. Inadequate response or inability to tolerate ONE of the following: 
    1. corticosteroids; or
    2. imunoglobulins; or
    3. splenectomy; or
    4. Rituxan (rituximab); and
  4. Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding; and
  5.  Prescribed by or in consultation with a hematologist/oncologist; and
  6. Member is 18 years of age or older
Initial authorization duration: 2 years

CONTINUATION CRITERIA: Eltrombopag olamine (Promacta®), Fostamitinib (Tavalisse™), Avatrombopag (Doptelet®) is re-approved when ALL of the following are met:

  1. Diagnosis of chronic immune (idiopathic) thrombocytopenic purpura; and
  2. Documentation of a positive clinical response to Promacta®, Tavalisse™, Doptelet® therapy as evidence by an increase in platelet count to a level sufficient to avoid clinically important bleeding; and
  3. Prescribed by or in consultation with a hematologist/oncologist

Continuation authorization duration: 2 years.

Aplastic anemia

INITIAL CRITERIA: Eltrombopag olamine (Promacta®) is approved when ALL of the following are met:

  1. Diagnosis of severe aplastic anemia; and
  2. Member is 2 years of age or older; and
  3. One of the following:
    1. Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine; or
    2. Documentation that the requested drug will be used in combination with antithymocyte globulin (ATG) and cyclosporin and
  4. Member has thrombocytopenia defined as platelet count less than 30,000/mcL; and
  5. Prescribed by or in consultation with a hematologist/oncologist

Initial authorization duration: 2 years

CONTINUATION CRITERIA: Eltrombopag olamine (Promacta®) is re-approved when ALL of the following are met:

  1. Diagnosis of relapsed/refractory chronic immune (idiopathic) thrombocytopenic purpura (ITP) or severe aplastic anemia; and
  2. Documentation of a positive clinical response to Promacta therapy; and
  3. Prescribed by or in consultation with a hematologist/oncologist

Continuation authorization duration: 2 years

Thrombocytopenia associated with hepatitis C

INITIAL CRITERIA: Eltrombopag olamine (Promacta®) is approved when ALL of the following are met:

  1. Diagnosis of thrombocytopenia associated with hepatitis C; and
  2. Member is 18 years of age or older; and
  3. ONE of the following:
    1. Member has thrombocytopenia defined as platelets less than 90,000/mcL for initiation (pre-treatment) of interferon-based therapy; or
    2. Member has thrombocytopenia defined as platelets less than 75,000/mcL for maintenance of optimal interferon-based therapy; and
  4. Prescribed by or in consultation with one of the following:
    1. Hematologist/ oncologist
    2. Gastroenterologist
    3. Hepatologist
    4. Infectious disease specialist
    5. HIV specialist

Initial authorization duration: 48 weeks

CONTINUATION CRITERIA: Eltrombopag olamine (Promacta®) is re-approved when ALL of the following are met:

  1. Diagnosis of thrombocytopenia associated with hepatitis C; and
  2. ONE of the following:
    1. For members that started treatment with Promacta prior to initiation of treatment with interferon, BOTH of the following:
      1. Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, and
      2. Member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9; or
    2. For members that started treatment with Promacta while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C; and
  3. Prescribed by or in consultation with one of the following:
    1. Hematologist/ oncologist
    2. Gastroenterologist
    3. Hepatologist
    4. Infectious disease specialist
    5. HIV specialist

Continuation authorization duration: 48 weeks

Thrombocytopenia in Chronic Liver Disease Prior to Planned Procedure

Lusutrombopag (Mulpleta®) or Avatrombopag (Doptelet®) is approved when ALL of the following are met:

  1. Diagnosis of thrombocytopenia; and
  2. Member has chronic liver disease; and
  3. Member is scheduled to undergo a procedure; and
  4. Baseline platelet count is less than 50,000/mcL; and
  5. Member is 18 years of age or older

Approval duration: 1 month

Eltrombopag olamine (Promacta®):

1.     Risk For Hepatic Decompensation In Patients With Chronic Hepatitis C

  • In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. 

2.     Eltrombopag may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended.

“Aplastic Anemia." Genetic and Rare Diseases Information Center, National Institute of Health, 5 July 2017, rarediseases.info.nih.gov/diseases/5836/aplastic-anemia. Accessed June 22, 2023.

Dahal, Sumit, et al. “Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection." Advances in Pediatrics., U.S. National Library of Medicine, 1 Mar. 2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5333732/. Accessed June 22, 2023.

Doptelet® (avatrombopag) [package insert]. Durham, NC. AkaRx, Inc. July 2021. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852&type=display. Accessed June 22, 2023.

Eltrombopag olamine (Promacta®) [package insert]. Basel, Switzerland. Novartis Pharmaceuticals Co. Ltd. March 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2&type=display. Accessed June 22, 2023.

Mulpleta® (lusutrombopag) [package insert]. Florham Park, NJ. Shionogi Inc., April 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9fd0cfd-717d-4a87-99bc-de7b38807e55&type=display. Accessed June 22, 2023.

Shah, N. MD, Intagliata, N, MD. December 2021. Hemostatic abnormalities in patients with liver disease. UpToDate. Access June 22, 2023.

“Idiopathic Thrombocytopenic Purpura (ITP)." Mayo Clinic, Mayo Foundation for Medical Education and Research, 9 Aug. 2017, www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/diagnosis-treatment/drc-20352330. Accessed June 22, 2023.

Tavalisse™ (fostamatinib) [package insert]. San Francisco, CA. Rigel Pharmaceutical, Inc. November 2020. Available from: https://tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf. Accessed June 22, 2023.


96/8/20236/8/202410/1/2023 1:26 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off Label Use

Brand NameGeneric Name
Promacta®Eltrombopag olamine
Tavalisse™fostamatinib
Doptelet®avatrombopag
Mulpleta®lusutrombopag
386
  
7/1/2024Rx.01.262CommercialOyenusi, OluwadamilolaQ1-2024

Immunoglobulin A nephropathy (IgAN) or Berger's disease is a condition that damages the glomeruli inside the kidneys and can cause kidney disease. The kidney gets inflamed and can cause the kidneys to leak blood and protein which leads to loss of kidney function and kidney failure. 

Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. Mucosal B-cells present in the ileum, including the Peyer's patches, express glucocorticoid receptors and are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy. Through their anti-inflammatory and immunosuppressive effects at the glucocorticoid receptor, corticosteroids can modulate B-cell numbers and activity. It has not been established to what extent TARPEYO's efficacy is mediated via local effects in the ileum vs systemic effects.

TARPEYO is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.


The intent of this policy is to communicate the medical necessity criteria for Budesonide (Tarpeyo™) as provided under the member's prescription drug benefit. 

Budesonide (Tarpeyo™) is approved when ALL of the following are met:

  1. Diagnosis of primary immunoglobulin A nephropathy (IgAN) as confirmed by a kidney biopsy; and
  2. Member is 18 years of age or older; and
  3. Member is at risk of rapid disease progression (e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool); and
  4. Used to reduce proteinuria; and
  5. Estimated glomerular filtration rate (eGFR) greater than or equal to 35 ml/min/1.73 m2; and
  6. One of the following:
    1. Member has been on a minimum 90-day trial of maximally tolerated dose and will continue to receive therapy with one of the following:
      1. An angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril); or
      2. An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan); or
    2. Member is unable to tolerate BOTH ACE inhibitors and ARBs; and
  7. Inadequate response or inability to tolerate another glucocorticoid (e.g., prednisone, methylprednisolone); and
  8. Prescribed by or in consultation with a nephrologist

Authorization duration: 9 months


None

Tarpeyo (budesonide) [package insert]. Stockhelm, Sweden: Calliditas Therapeutics AB. December 2021. Available at: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=938cada4-d6bf-4252-836f-dd40f9eadb4d. Accessed April 17, 2024. 

Cattran DC. IgA nephropathy: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 17, 2024. 


33/14/20243/14/20257/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
​Rx.01.33 Off Label Use​
Brand NameGeneric Name
Tarpeyo™Budesonide

NANA
292
  
1/1/2024Rx.01.10CommercialOyenusi, Oluwadamilola

Hyperammonemia is a urea cycle disorder due to a deficiency of an enzyme in the pathway that can cause life-threatening metabolic decompensations in infancy. Survivors frequently have severe neurologic injury. Frequent vomiting and poor appetite with food refusal and protein aversion are common in patients with UCD. In newborns, central hyperventilation leading to respiratory alkalosis is an early sign of hyperammonemia. Infants become symptomatic after feeding in which initial signs include somnolence, inability to maintain normal body temperature, poor feeding followed by vomiting lethargy and coma.


 

N-acetylglutamate synthetase (NAGS) deficiency is a rare, autosomal, recessive genetic disorder in which lack of NAGS enzyme leads to hyperammonemia (excess ammonia).  NAGS deficiency is one of several urea cycle disorders.


Carglumic acid (Carbaglu®) is a synthetic structural analogue of N-acetylglutamate (NAG), which is produced from glutamate and acetyl-CoA in a reaction catalyzed by N-acetylglutamate synthase (NAGS), a mitochondrial liver enzyme. NAG acts as an essential allosteric activator of carbamoyl phosphate synthetase 1 (CPS 1) in liver mitochondria. CPS 1  catalyzes the first reaction  of the urea cycle, . NAG is the product of NAGS, a mitochondrial liver enzyme. Carglumic acid acts as a CPS 1 activator   in NAGS deficiency patients , thereby facilitating ammonia detoxification and urea production by removing the block in the urea cycle

Carglumic Acid (Carbaglu®) is indicated for adjunctive therapy in the treatment of acute hyperammonemia due to NAGS deficiency, propionic acidemia (PA) or methylmalonic acidemia (MMA), and maintenance therapy of chronic hyperammonemia due to the deficiency of the hepatic enzyme NAGS.

The intent of this policy is to communicate the medical necessity criteria for carglumic acid (Carbaglu®) as provided under the member's prescription drug benefit.

Acute Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency

APPROVAL CRITERIA: Carglumic Acid (Carbaglu®) is approved when all of the following are met:

  1. Diagnosis of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; and 
  2. Medication will be used as adjunctive therapy to other ammonia lowering therapies (e.g., protein restriction, ammonia scavengers, dialysis) 
  3. Prescribed by or in consultation with a provider who specializes in the treatment of metabolic disorders

Authorization duration: 3 months

Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)

APPROVAL CRITERIA: Carglumic Acid (Carbaglu®) is approved when all of the following:

  1. Diagnosis of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA); and
  2. Medication will be used as adjunctive therapy to other ammonia lowering therapies (e.g., intravenous glucose, insulin, protein restriction, dialysis); and
  3. Patient's plasma ammonia level is greater than or equal to 50 micromol/L; and
  4. Medication will be used for a maximum duration of 7 days; and
  5. Prescribed by or in consultation with a provider who specializes in the treatment of metabolic disorders


​Authorization duration: 3 months

Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency

INITIAL CRITERIA: Carglumic Acid (Carbaglu®) is approved when all of the following:

  1. Diagnosis of chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; and
  2. NAGS deficiency has been confirmed by genetic/mutational analysis; and
  3. Medication will be used as maintenance therapy; and
  4. Prescribed by or in consultation with a provider who specializes in the treatment of metabolic disorders

Initial authorization duration: 2 years

​REAUTHORIZATION CRITERIA: Carglumic acid (Carbaglu®) is re-approved when there is documentation of positive clinical response to therapy (e.g., plasma ammonia level within the normal range).


Reauthorization duration: 2 years​




N/A

Carbaglu® [package insert]. Lebanon NJ. Recordati Rare Diseases, Inc.  September 2021. Available at: https://www.carbaglu.com/wp-content/uploads/2020/01/carbaglu-prescribing-information.pdf. Accessed NOVEMBER 21, 2023.

N-acetylglutamate synthetase deficiency. National organization for rare disorders. Available at: http://rarediseases.org/rare-diseases/n-acetylglutamate-synthetase-deficiency/. Accessed NOVEMBER 21, 2023.

Lee B. Urea cycle disorders: clinical features and diagnosis. UpToDate website. June 2021. Available at http://www.uptodate.com/. Accessed Accessed NOVEMBER 21, 2023.


 


 

149/14/20239/14/20241/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
Off-Labe Use Rx01.33
 

Brand Name Generic Name
Carbaglu® Carglumic Acid
265
  
10/1/2023Rx.01.217CommercialOyenusi, Oluwadamilola

 

Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by impairment in the first branch of the trigeminal nerve which leads to a decrease in or absence of corneal sensitivity. Loss of sensitivity impairs wound healing, leading to corneal epithelial breakdown, development of ulcerations, melting of the stroma, and corneal perforation. Diagnosis, prognosis, and treatment are based on disease severity, which is classified into 3 stages. Stage 1 (mild) NK is characterized by ocular surface irregularity and reduced vision; stage 2 (moderate) is characterized by a non-healing persistent epithelial defect (PED); and stage 3 (severe) exhibits corneal ulceration involving subepithelial (stromal) tissue, which may progress to corneal melting and perforation.  

Therapy for stage 1 disease aims to prevent epithelial breakdown, generally by administering preservative-free artificial tears and discontinuing all topical and systemic medications associated with ocular surface toxicity. The use of punctal plugs may also help increase tear volume. The goal of treatment for stage 2 NK is to promote healing of the epithelial defect and to avoid the development of a corneal ulcer. In addition to the therapies in the previous stage, topical antibiotics are recommended to prevent infections. Therapeutic corneal or scleral contact lenses may be used to promote healing; however, there may be an increased risk of secondary infections. Autologous serum eye drops, which contain components of natural tears, have increasingly been used to treat ocular surface disorders including NK. The main goal of treatment at stage 3 is to prevent corneal thinning and perforation. Various surgeries and procedures are available to treat ulcers not responding to medical treatment. Tarsorrhaphy is the most commonly used procedure to promote corneal healing. Alternative treatments include botulinum-induced ptosis, amniotic membrane transplantation, eyelid closure with tape, patching, and use of the conjunctival flap to cover the corneal surface.

Cenegermin-bkbj (Oxervate™) is a novel recombinant human nerve growth factor (rhNGF) produced in Escherichia coli that is structurally identical to human NGF. NGF is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity and low affinity NGF receptors in the anterior segment of the eye to support corneal innervation and integrity. Cengermin-bkbj (Oxervate™) is the first FDA-approved pharmacologic therapy indicated for the treatment of neurotropic keratitis (NK). Oxervate™ is an 8-week treatment cycle per affected eye(s).




 

​The intent of this policy is to communicate the medical necessity criteria for cenegermin-bkbj (Oxervate™) as provided under the member’s prescription drug benefit.

INITIAL CRITERIA Cenegermin-bkbj (Oxervate™) is approved when ALL of the following are met:

  1. Diagnosis of Stage 2 or 3 neurotrophic keratitis; and
  2. Documentation of an inadequate response or inability to tolerate at least one over-the-counter ocular lubricant used at an optimal dose and frequency for at least two weeks (e.g., artificial tears, lubricating gels/ointments, etc.); and
  3. Prescribed by or in consultation with an ophthalmologist; and
  4. Submission of chart documentation indicating treatment of left eye, right eye, or both; and
  5. Member will not exceed 8 weeks of Oxervate therapy per affected eye(s)

Initial authorization duration: 3 months

REAUTHORIZATION CRITERIA Cenegermin-bkbj (Oxervate™) is re-approved when ALL of the following are met:
  1. Submission of chart documentation indicating treatment of left eye, right eye, or both; and
  2. One of the following:
    1. Member has received less than or equal to 8 weeks of therapy (one course of therapy) per affected eye(s); and
    2. Documentation of clinical rationale for treatment greater than 8 weeks (e.g., member has a recurrence of neurotropic keratitis in the same eye, or treatment of a different eye); and
  3. Documentation of clinical response to prior Oxervate™ therapy; and
  4. Member will not exceed a total of 16 weeks of Oxervate™ therapy per affected eye(s); and
  5. Prescribed by or in consultation with an ophthalmologist

Reauthorization duration: 3 months

Lifetime limit: 16 weeks of therapy per affected eye



 

None

 

Bonini S, Lambiase A, Rama P, et al.; REPARO Study Group. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332-1343. Accessed June 22, 2023.

Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2019; 66:107-131. Accessed June 22, 2023.

Oxervate® (cenegermin-bkbj) [prescribing information]. Boston, MA: Dompe U.S. Inc. October 2019. Available at:  https://oxervate.com/pdf/PrescribingInformation.pdf. Accessed June 22, 2023.

Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020 Jan;127(1):14-26. Accessed June 22, 2023.

Pocobelli A, Komaiha C, De Carlo L, Pocobelli G, Boni N, Colabelli Gisoldi RAM. Role of Topical Cenegermin in Management of a Cornea Transplant in a Functionally Monocular Patient with Neurotrophic Keratitis and Facial Nerve Palsy: A Case Report. Int Med Case Rep J. 2020 Nov 11;13:617-621. Acccessed June 22, 2023.

Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratisis. Clin Ophthalmol. 2014; 8:571-579. Accessed June 22, 2023.

Semeraro F, Forbice E, Romano V, et al. Neurotrophic keratitis. Opthalmologica. 2014;231(4):191-197. Accessed June 22, 2023.

Versura P, Giannaccare G, Pellegrini M, Sebastiani S, Campos EC. Neurotrophic keratitis: current challenges and future prospects. Eye Brain. 2018; 10:37-45. Accessed June 22, 2023.


86/8/20236/8/202410/1/2023 1:27 AMNo presence informationsrv_ppsgw_P

​Rx.01.33 Off-Label Use
Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit

Brand Name
Generic Name
Oxervate™cenegermin-bkbj
296
  
1/1/2024Rx.01.22CommercialOyenusi, Oluwadamilola

Individuals, who are transfusion-dependent, receive excess iron with each transfusion.  In non-transfusion-dependent thalassemia (NTDT), elevated iron levels are related to suppression of hepcidin levels, increased intestinal iron absorption, and increased release of recycled iron from the reticuloendothelial system.  The excess iron accumulates in various tissues, including cardiac, liver, pulmonary, and endocrine glands, due to lack of an active mechanism to excrete iron.  The goal of iron chelation therapy in iron overload is to reduce iron levels, prevent complications, and reduce morbidity.

Deferasirox (Exjade®/ Jadenu®) is indicated for the treatment of transfusional hemosiderosis (chronic iron overload due to blood transfusions) in individuals who are 2 years of age or older and for the treatment of chronic iron overload in patients 10 years of age and older with NTDT syndromes and with a liver iron concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/ g dw) and a serum ferritin greater than 300 mcg/L.

Deferiprone (Ferriprox®) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.

Deferasirox (Exjade®/Jadenu®) is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper, there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.


Deferiprone (Ferriprox®) is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.

The intent of this policy is to communicate the medical necessity criteria for deferasirox (Exjade®/ Jadenu®) and deferiprone (Ferriprox®) as provided under the member's prescription drug benefit.​

Chronic iron overload in blood transfusions dependent anemia

INITIAL CRITERIA: Deferasirox (Exjade®/Jadenu®) is approved when ALL of the following are met:

  1. Diagnosis of chronic iron overload due to blood transfusions; and
  2. Member is 2 years of age or older; and
  3. Serum ferritin levels are consistently greater than 1000 mcg/L (as demonstrated with at least two lab values within two months prior to treatment)
  4. For Brand Exjade and Brand Jadenu only, inadequate response or inability to tolerate generic deferasirox

Initial authorization duration: 12 months

 
​​CONTINUATION CRITERIA: Deferasirox (Exjade®/Jadenu®) is re-approved there is documentation of a decreased serum ferritin level compared with baseline level for transfusion dependent anemia.

Continuation duration: 2 years​


INITIAL CRITERIA: Deferiprone (Ferriprox®) is approved when all of the following are met:

  1. Diagnosis of transfusional iron overload due to Sickle Cell disease or other transfusion-dependent anemia; and
  2. Member is 3 years of age or older; and
  3. Inadequate response or inability to tolerate one of the following chelation therapy:
    1. Generic deferoxamine; or
    2. generic deferasirox; and
  4. For Brand Ferriprox tablets only, Inadequate response or inability to tolerate generic deferiprone tablets; and
  5. Current chelation therapy is inadequate

Initial authorization duration: 12 months


​​CONTINUATION CRITERIA: Deferiprone (Ferriprox®) is re-approved when there is documentation of positive clinical response to therapy (e.g., decline in serum ferritin levels from baseline).

Continuation duration: 2 years​


Chronic iron overload in non-transfusion-dependent Thalassemia Syndrome

INITIAL CRITERIA: Deferasirox (Exjade®/Jadenu®) is approved when ALL of the following are met:

  1. Diagnosis of chronic iron overload in Non-Transfusion-Dependent Thalassemia Syndromes; and
  2. Member is 10 years of age or older; and
  3. Serum ferritin levels are consistently greater than 300 mcg/L and liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) (as demonstrated with at least two lab values within 2 months prior to treatment)

Initial authorization duration: 12 months

 
CONTINUATION CRITERIA: Deferasirox (Exjade®/Jadenu®) is re-approved when there is documentation of a decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration) for non-transfusion dependent Thalassemia Syndrome

Continuation duration: 2 years


INITIAL CRITERIA: Deferiprone (Ferriprox®) is approved when ALL of the following are met:

  1. Diagnosis of transfusional iron overload due to Thalassemia Syndrome; and
  2. Member is 3 years of age or older; and
  3. Inadequate response or inability to tolerate one of the following chelation therapy:
    1. Generic deferoxamine; or
    2. Generic deferasirox; and
  4. For Brand Ferriprox tablets only, Inadequate response or inability to tolerate generic deferiprone tablets; and
  5. Current chelation therapy is inadequate

Initial authorization: 12 months
 
​​CONTINUATION CRITERIA: Deferiprone (Ferriprox®) is re-approved when there is documentation of positive clinical response to therapy (e.g., greater than or equal to 20% decline in serum ferritin levels from baseline).

Continuation duration: 2 years​


 

 

Deferasirox (Exjade/ Jadenu)

Renal failure: Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Deferasirox is contraindicated in adults and pediatric patients with eGFR less than 40 ml/min/1.73m2. Use caution in pediatric patients with eGFR between 40 and 60 ml/min/1.3m2. For patients with renal impairment (eGFR 40-60 ml/min/1.73m2) reduce starting dose by 50%. Measure serum creatinine and determine creatinine clearance (CrCl)prior to initiation of therapy and monitor renal function at least monthly thereafter. For patients with baseline renal impairment or increased risk of acute renal failure, monitor creatinine weekly for the first month, then at least monthly thereafter. Monitor serum ferritin monthly to evaluate for overchelation. Use the minimum dose to establish and maintain a low iron burden. Consider dose reduction, interruption, or discontinuation based on increases in serum creatinine. Interrupt deferasirox therapy when acute kidney injury is suspected and during volume depletion.

Hepatic failure: Deferasirox can cause hepatic injury including hepatic failure and death. Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter. Avoid use of deferasirox in patients with severe (Child-Pugh class C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh class B) hepatic impairment. Interrupt deferasirox therapy when acute liver injury is suspected and during volume depletion.

GI hemorrhage: Deferasirox can cause GI hemorrhages, which may be fatal, especially in elderly patients who have advanced hematologic malignancies and/or low platelet counts. Monitor patients and discontinue deferasirox for suspected GI ulceration or hemorrhage.

Deferiprone (Ferriprox)

Agranulocytosis/Neutropenia: Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor the ANC weekly during therapy. Interrupt deferiprone therapy if neutropenia develops. If infection develops, interrupt deferiprone and monitor the ANC more frequently. Advise patients taking deferiprone to report immediately any symptoms indicative of infection. For neutropenia, instruct the patient to immediately discontinue deferiprone and all other medications with potential to cause neutropenia. Obtain a complete blood count (CBC), white blood count (WBC corrected for the presence of nucleated red blood cells, ANC and a platelet count daily until recovery. For agranulocytosis, consider hospitalization and other clinically appropriate management.


 



Biyani CS. Cystinuria. Available at http://emedicine.medscape.com/article/435678-overview. Accessed November 15, 2023.

 Exjade (deferasirox) [package insert]. East Hanover NJ. Novartis Pharmaceuticals Corporation.  Revised July 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3495a70c-870c-4968-940e-8baea152cf85&type=display. Accessed November 15, 2023.

Ferriprox (deferiprone) [package insert]. Rockville MD. ApoPharma USA, Inc.  Revised  May 2020.  Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=97f7bfcb-8666-464c-87b6-9621ceca5ee2&type=display. Accessed November 15, 2023.

 Gilroy RK. Wilson Disease. Available at: http://emedicine.medscape.com/article/183456-overview#a1. Accessed November 15, 2023.

Jadenu (deferasirox) [package insert]. East Hanover NJ. Novartis Pharmaceuticals Corporation. Revised July 2020. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee89140-fff1-4443-9f42-24ac004fcda1. Accessed November 15, 2023.

 Mir M. Transfusion induced iron overload. Available at: http://emedicine.medscape.com/article/1389732-overview. Accessed November 15, 2023.

Musallam KM, Rivella S, Vichinsky E, Rachmilewitz. Non-transfusion-dependent thalassemias. Haematologica. June 2013;98:833-844. DOI: 10.3324/haematol.2012.066845


 

159/14/20239/14/20241/1/2024 1:24 AMNo presence informationsrv_ppsgw_P

Off-Label Use policy Rx.01.33


Brand NameGeneric Name
ExjadeDeferasirox
JadenuDeferasirox
Ferriprox
Deferiprone


 

248
  
10/1/2023Rx.01.131CommercialOyenusi, Oluwadamilola

Lomitapide a synthetic lipid-lowering agent, directly binds and inhibits microsomal triglyceride transfer protein, which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and very low-density lipoprotein (VLDL). The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.

Lomitapide (Juxtapid®) is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Proprotein convertase subtilisin/ kexin type 9 (PCSK9) is a serine protease synthesized primarily by the liver and intestines.  PCSK9 promotes the degradation of low density lipoprotein (LDL) receptors, thus preventing them from being recycled back to the plasma membrane where they can bind more LDL. Inhibitors of PCSK9 increase recycling of LDL receptors which in turn increases the capacity to remove LDL cholesterol (LDL-C) from the blood. These agents are monoclonal antibodies administered subcutaneously.

Alirocumab (Praluent®) and evolocumab (Repatha®) are indicated:

  • in adults with established cardiovascular disease (CVD) to reduce the risk of myocardial infarction, stroke, and coronary revascularization ​
  • as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C 
  • as an adjunct to other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C 

According to current guidelines, HMG-CoA reductase inhibitors (statins) are the mainstay of pharmacologic therapy for treating elevated LDL-C for both primary and secondary prevention of atherosclerotic cardiovascular disease.  Lifestyle modifications are a critical component of treating elevated LDL-C and should be used in conjunction with pharmacologic therapy.  

Clinical trials of PCSK9 inhibitors demonstrated reductions in LDL-C approximately 50-60%.  Reauthorization criteria will include a reduction from baseline of 25% or greater, which will assess adherence with the medication.

Bempedoic acid (Nexletol™) is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver.  ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway.  Bempedoic ​acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively.  ACSVL1 is expressed primarily in the liver.  Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.  The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols.  Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.  This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.

Bempedoic acid (Nexletol™) and bempedoic acid/ezetimibe (Nexlizet™) is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.



 


The intent of this policy is to communicate the medical necessity criteria for lomitapide (Juxtapid®), alirocumab (Praluent®), evolocumab (Repatha®), bempedoic acid (Nexletol™), and bempedoic acid/ezetimibe (Nexlizet™) as provided under the member's prescription drug benefit.

INITIAL CRITERIA: Lomitapide (Juxtapid®) is approved when  ALL of the following are met:

  1. Diagnosis of Homozygous Familial Hypercholesterolemia; and
  2. Used as an adjunct to lipid lowering treatments and a low-fat diet with ONE of the following:
    1. Genetic confirmation of 2 mutant alleles at the LDL receptor, Apo B, PCSK9, or LDL receptor adaptor protein 1 (i.e. LDLRAP1 or ARH); or
    2. Untreated LDL-C > 500mg/dL or treated LDL cholesterol ≥ 300mg/dL with either of the following:
      1. Cutaneous or tendinous xanthoma prior to 10 years of age, or
      2. Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents; AND
  3. ONE of the following:
    1. Inadequate response to one of the following medications in combination with ezetimibe:
      1. Simvastatin (daily doses ≥ 40mg); or
      2. Atorvastatin (daily doses ≥ 20mg); or
      3. Rosuvastatin (daily doses ≥ 10mg); or
    2. Member has experience ONE of the following:
      1. Rhabdomyolysis or muscle symptoms with creatine kinase (CK) elevations > 10 times upper limit of normal (ULN) on any statin; or
      2. Myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations < 10 times ULN) with TWO statins; AND
  4. Inadequate response or inability to tolerate evolocumab (Repatha®) or alirocumab (Praluent®); and
  5. Prescribed by or in consultation with one of the following:
    1. Cardiologist; or
    2. Endocrinologist; or
    3. Lipid specialist
​Initial authorization duration: 6 months

Reauthorization criteria: Lomitapide (Juxtapid®) is re-approved when there is a reduction in LDL level of at least 25% since initiation of therapy.

Reauthorization duration: 12 months

 

INITIAL CRITERIA: Alirocumab (Praluent®) is approved when ALL of the following are met:

  1. Diagnosis of ONE of the following:
    1. Hyperlipidemia; or
    2. Homozygous familial hypercholesterolemia and one of the following:
      1. Diagnosis confirmed by genetic test; or
      2. Untreated LDL-C >500mg/dL with either of the following:
        1. Cutaneous or tendinous xanthoma prior to 10 years of age; or 
        2. Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents; or
    3. Atherosclerotic cardiovascular disease as diagnosed by either stress test, angiography, atherosclerotic event (e.g., MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic diseases (e.g., coronary, peripheral, carotid); and
  2. ONE of the following:
    1. LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy; or
    2. Inability to tolerate statin therapy as documented by ONE of the following:
      1. Member has rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) on any statin; or
      2. ONE of the following with TWO statins:
        1. Myalgia (no CK elevation); or
        2. Myositis (CK less than 10 times ULN); or
        3. Hepatotoxicity from statin use (increase AST/ALT exceeding 3 times ULN); OR
      3. Liver disease documented by Child Pugh A or worse or AST/ALT exceeding 3 times ULN for at least 6 weeks; and
  3. Inadequate response or inability to tolerate evolocumab (Repatha®)
Initial authorization duration: 6 months.


REAUTHORIZATION CRITERIA Alirocumab (Praluent®) is re-approved when there is a sustained reduction in LDL-C of at least 25% since initiation of therapy.

Reauthorization duration: 12 months

 

INITIAL CRITERIA: Evolocumab (Repatha®) is approved when ALL of the following are met:

  1. Diagnosis of ONE of the following:
    1. Hyperlipidemia; or
    2. Homozygous familial hypercholesterolemia and one of the following:
      1. Diagnosis confirmed by genetic test; or
      2. Untreated LDL-C >500mg/dL with either of the following:
        1. Cutaneous or tendinous xanthoma prior to 10 years of age; or
        2. Elevated LDL cholesterol prior to lipid-lowering therapy consistent with HeFH in both parents; or
    3. Atherosclerotic cardiovascular disease as diagnosed by either stress test, angiography, atherosclerotic event (e.g., MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g., coronary, peripheral, carotid); AND
  2. ONE of the following:
    1. LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy; or
    2. Inability to tolerate statin therapy as documented by ONE of the following:
      1. Member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) on any statin; or
      2. ONE of the following with TWO statins:
        1. Myalgia (no CK elevation); or
        2. Myositis (CK less than 10 times ULN; or
        3. Hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN); OR
      3. Liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks​


Initial Authorization duration: 6 months

Reauthorization criteria:  Evolocumab (Repatha®) is re-approved when there is a sustained reduction in LDL-C of at least 25% since initiation of therapy

Reauthorization duration: 12 months

 

INITIAL CRITERIA: Bempedoic acid (Nexletol™), bempedoic acid/ezetimibe (Nexlizet™) is approved when ALL of the following are met:

  1. One of the following diagnoses:
    1. Heterozygous familial hypercholesterolemia (HeFH); or
    2. Atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g., MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic diseases (e.g., coronary, peripheral, carotid); and
  2. One of the following:
    1. LDL-C 70 mg/dL or greater after at least 8 consecutive weeks of statin therapy and member will continue to receive statin therapy at maximally tolerated dose; or
    2. Inability to tolerate statin therapy as documented by ONE of the following:
      1. Member has rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) on any statin; or
      2. ONE of the following with TWO statins:
        1. Myalgia (no CK elevation); or
        2. Myositis (CK less than 10 times ULN); or
        3. Hepatotoxicity from statin use (increase AST/ALT exceeding 3 times ULN); or
      3. Liver disease documented by Child Pugh A or worse or AST/ALT exceeding 3 times ULN for at least 6 weeks; and
  3. ONE of the following:
    1. Member has been receiving at least 8 consecutive weeks of ezetimibe (Zetia®) therapy as adjunct to maximally tolerated statin therapy; or
    2. Member has contraindication or intolerance to ezetimibe (Zetia®)

      Initial Authorization duration: 6 months

REAUTHORIZATION CRITERIA: Bempedoic acid (Nexletol™), Bempedoic acid/ezetimibe (Nexlizet™) is approved when ALL of the following are met:

  1. Documentation of sustained reduction of LDL-C by at least 17% from the time therapy began or sustained below 70mg/dL; and
  2. ONE of the following:
    1. Member continues to receive other lipid-lowering therapy (e.g., statins, ezetimibe) at the maximally tolerated dose; or
    2. Member has inability to tolerate other lipid-lowering therapy (e.g., statins, ezetimibe)

Reauthorization duration: 12 months

 

Risk of hepatotoxicity:

Lomitapide (Juxtapid®) can cause elevations in transaminases. In clinical trials, of patients treated with lomitapide had at least 1 elevation in ALT or AST at least 3 times the upper limit of normal (ULN) or higher. There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), alkaline phosphatase or partial thromboplastin time (PTT).

Lomitapide also increase hepatic fat (hepatic steatosis), with or without concomitant increase in transaminases. In the trials of patients with heterozygous familial hypercholesterolemia and hyperlipidemia, the median absolute increase in hepatic fat was 6% (lomitapide) after 26 weeks of treatment from 0% at baseline, measured by magnetic resonance imaging (MRI) and 1% at baseline, measured by magnetic resonance spectroscopy (MRS) respectively. Hepatic steatosis is a risk factor for advanced liver disease, including steatohepatitis and cirrhosis.

 

Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT and AST regularly as recommended. During treatment, adjust the dose of lomitapide if the ALT or AST are at least 3 times the ULN. Discontinue lomitapide for clinically significant liver toxicity.

 

Because of the risk of hepatotoxicity, lomitapide are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).​

Farnier M, Bruckert E. Severe familial hypercholesterolemia: Current and future management. Arch Cardiovasc Dis. 2012 Dec; 105(12):656-65. Accessed June 23, 2023.


Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis, and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidology. 2011;5:S1-S8. Accessed June 23, 2023.


Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110:227-39. Accessed June 23, 2023.


Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for the patient-centered management of dyslipidemia: Part 1- full report. J Clin Lipidology. 2015;9:129-69. Accessed June 23, 2023.


Juxtapid® (lomitapide) [prescribing information.] Cambridge, MA. Aegerion Pharmaceuticals. December 2019. Available at: http://juxtapidpro.com/prescribing-information. Accessed June 23, 2023.


Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8. Accessed June 23, 2023.


Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. Circulation. 2013. Available from: http://circ.ahajournals.org/cgi/content/short/129/25_suppl_2/S1?rss=1&ssource=mfr. Accessed June 23, 2023.


Visser ME, Witztum JL, Stroes ES, et al. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012 Jun; 33(12):1451-8. doi: 10.1093/eurheartj/ehs084. Epub 2012 May 24.


Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012; 53(12): 2515-24. DOI: 10.1194/jlr.R026658. Accessed June 23, 2023.


Farnier M. PCSK9: From discovery to therapeutic applications. Arch Cardiovascular Dis. 2014; 107: 58-66. DOI: 10.1016/j.acvd.2013.10.007. Accessed June 23, 2023.


Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis, and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidology. 2011;5:S1-S8. Accessed June 23, 2023


Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for the patient-centered management of dyslipidemia: Part 1- full report. J Clin Lipidology. 2015;9:129-69. Accessed June 23, 2023.


Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly Jr DD, DePalma SM, Minissian, MB, Orringer CE, Smith Jr SC, 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Exper Decision Consensus Pathways. Journal of the American College of Cardiology (2017), doi: 10.1016/j.jacc.2017.07.745. Accessed June 23, 2023.


Nexletol™ (bempedoic acid) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics, Inc.; February 2020. Available from: https://pi.esperion.com/nexletol/nexletol-pi.pdf. Accessed June 23, 2023.


Nexlizet™ (bempedoic acid and ezetimibe) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics, Inc.; February 2020. Available from: https://pi.esperion.com/nexlizet/nexlizet-pi.pdf. Accessed June 23, 2023.


Praluent® (alirocumab) [package insert]. Bridgewater, NJ. Sanofi-Aventis US LLC. April 2021.  Available from: http://products.sanofi.us/praluent/praluent.pdf. Accessed June 23, 2023.


Repatha® (evolocumab) [package insert]. Thousand Oaks, CA. Amgen Inc. February 2021. Available from: https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/repatha/repatha_pi_hcp_english.pdf. Accessed June 23, 2023.


Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. Circulation. 2013. https://doi.org/10.1161/01.cir.0000437738.63853.7a. Accessed June 23, 2023.


Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol. 2014;7:107-17. Accessed June 23, 2023.


156/8/20236/8/202410/1/2023 1:24 AMNo presence informationsrv_ppsgw_P

Off-Label Use Rx.01.33


Brand nameGeneric name
Juxtapid®Lomitapide
Praluent®alirocumab
Repatha®evolocumab
Nexletol™Bempedoic acid
Nexlizet™Bempedoic acid/ezetimibe

339
  
4/1/2024Rx.01.171CommercialOyenusi, OluwadamilolaQ4-2023

Bile acid synthesis disorders (BASD) are extremely rare, genetic, metabolic conditions that exhibit manifestations of liver disease, steatorrhea, and complications from decreased fat soluble vitamin absorption.  Individuals with BASD lack the enzymes needed to synthesize cholic acid.  If untreated, these individuals fail to grow and can develop life-threatening liver injury. 

Cholic acid is a primary bile acid synthesized from cholesterol in the liver. In bile acid synthesis disorders due to single enzyme deficiencies (SEDs) in the biosynthetic pathway, and in peroxisomal disorders (PDs) including Zellweger spectrum disorders, deficiency of primary bile acids leads to unregulated accumulation of intermediate bile acids and cholestasis. Bile acids facilitate fat digestion and absorption by forming mixed micelles, and facilitate absorption of fat-soluble vitamins in the intestine.

Endogenous bile acids, including cholic acid, enhance bile flow and provide the physiologic feedback inhibition of bile acid synthesis. The mechanism of action of cholic acid has not been fully established; however, it is known that cholic acid and its conjugates are endogenous ligands of the nuclear receptor, farnesoid X receptor (FXR). FXR regulates enzymes and transporters that are involved in bile acid synthesis and in the enterohepatic circulation to maintain bile acid homeostasis under normal physiologic conditions.

Cholic acid (Cholbam®) is indicated for:

  1. The treatment of BASD due to SEDs
  2. Adjunctive treatment of PDs including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption.​

Treatment with cholic acid (Cholbam®) is approved for children aged 3 weeks and older, and adults.


The intent of this policy is to communicate the medical necessity criteria for cholic acid (Cholbam®) as provided under the member's prescription drug benefit.

INITIAL CRITERIA Cholic acid (Cholbam®) is approved when ALL of the following are met:

  1. One of the following:
    1. Treatment of bile acid synthesis disorder due to single enzyme defect; or
    2. Adjunctive treatment of peroxisomal disorder including Zellweger spectrum disorder in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption; and
  2. Prescribed by or in consultation with one of the following:
    1. hepatologist; or
    2. gastroenterologist; or
    3. medical geneticist; or
    4. other specialist that treats inborn errors of metabolism; and
  3. No documentation of extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorder

 

Initial authorization duration: 3 months

 

REAUTHORIZATION CRITERIA Cholic acid (Cholbam®) is re-approved when there is documentation of improved liver function tests (e.g., aspartate aminotransferase [AST], alanine aminotransferase [ALT]) from the start of treatment.

 

Reauthorization duration: 2 years


None
Cholbam® (Cholic acid) [package insert]. Baltimore MD. Asklepion Pharmaceuticals, LLC. May 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205750s000lbl.pdf. Accessed February 13, 2024

Cholic acid. Micromedex 2.0. Truven Health Analytics, Inc. Greenwood Village, CO.  Available from: http://www.micromedexsolutions.com. Accessed February 13, 2024

1012/18/202312/18/20244/1/2024 1:23 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use 
Cholbam®cholic acid
372
  
4/1/2024Rx.01.285CommercialOyenusi, OluwadamilolaQ4-2023
Patients with established cardiovascular disease (CVD) have a high risk of subsequent CVD events, including myocardial infarction (MI), stroke, and death.  Therapeutic lifestyle changes, which include increased physical activity, dietary modification/weight loss, and smoking cessation are of proven benefit and improve outcomes beginning within a matter of weeks. In addition, adjunctive drug therapies of proven benefit include statins and aspirin, whose benefits are at least additive.

The mechanism of action of colchicine in the prevention of major cardiovascular events is not understood. However, it is known that colchicine disrupts cytoskeletal functions through inhibition of β-tubulin polymerization into microtubules and consequently prevents the activation, degranulation, and migration of neutrophils. Colchicine may also interfere with the intracellular assembly of the inflammasome complex in neutrophils and monocytes that mediates activation of interleukin-1β. These anti-inflammatory effects are consistent with clinical data demonstrating that colchicine reduces high sensitivity C- reactive protein (hs-CRP).

Lodoco is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

The intent of this policy is to communicate the medical necessity criteria for Colchicine (Lodoco) as provided under the member's prescription drug benefit.

INITIAL CRITERIA: Colchicine (Lodoco) is approved when all of the following are met:

  1. Diagnosis of cardiovascular disease (CV); and
  2. Used for the secondary prevention of CV disease (e.g., very high-risk patients); and
  3. Member is 18 years of age or older; and
  4. Member is on guideline therapy management for multiple risk factors (e.g., dyslipidemia, hypertension, hyperglycemia) associated with CV disease

 

Initial authorization duration: 6 months

 

REAUTHORIZATION CRITERIA: Colchicine (Lodoco) is re-approved when documentation is provided of positive clinical response to therapy

 

Reauthorization duration: 6 months


N/A
Hennekens CH, Lopez-Sendon J. Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk. July 2023. In: UpToDate, Connor RF (Ed), Wolters Kluwer. Accessed February 15, 2024.

Lodoco (colchicine) [prescribing information]. Parsippany, NJ: AGEPHA Pharma USA, LLC. June 2023. Available from: https://lodoco.com/. Accessed February 15, 2024. 

112/18/202312/18/20244/1/2024 1:29 AMNo presence informationsrv_ppsgw_P
Off-Label Use Rx.01.33
Brand NameGeneric Name
​Lodoco

Colchicine

LODOCO       TAB 0.5MGCOLCHICINE (CARDIOVASCULAR) TAB 0.5 MG
249
  
10/1/2023Rx.01.134CommercialOyenusi, Oluwadamilola

The Food and Drug Administration (FDA) defines pharmacy compounding as the practice in which pharmacists combine, mix, or alter ingredients to create unique medications that meet the specific needs of an individual patient. Generally, drugs are compounded for patients that have allergic reactions to inactive ingredients in FDA approved products or for those patients who require a different formulation of a medication that is not commercially available.  

Compounding pharmacies are regulated by State Boards of Pharmacy and the FDA (if they are outsourcing facilities). For non-outsourcing facilities, drugs can be compounded only if certain conditions are met, such as, valid prescription requirement for an identified individual patient; or in limited quantities before obtaining the actual prescription by the pharmacy. Moreover, FDA restricts the production of essential copies of approved and unapproved non-prescription drugs.

A compounded product is not considered medically necessary when it replicates a commercially available product (unless the commercially available product is temporarily unavailable), contains a drug product or component that has been removed from the market because it is unsafe or not effective or contains a drug product or component that is excluded from the member's benefit. 


 

The intent of this policy is to communicate the medical necessity criteria for compounded products, consistent with Pharmacy Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, where at least one ingredient is a prescription drug, as provided under the member's prescription drug benefit.

This policy will also be used to review requests for ingredients which are not considered standard coverage under the prescription drug benefit that are used in compounded products.  This includes requests for injectable medications that are used as part of a compound for a route of administration other than injectable. 


 

A compounded product, including a commercially available compounding kit, is considered medically necessary when ALL of the following are met:

  1. The active prescription ingredient(s) of the compound is FDA approved or supported by accepted compendium as stated in the Off-Label Use policy for the indication and route of administration; AND

  2. The product as compounded is not commercially available. This may include a current short supply* of the commercially available product or the member has a medical need for a dosage form, strength or formulation other than what can be accomplished with a commercially available product; AND

  3. Member had an inadequate response or inability to tolerate all commercially available therapeutic alternatives to treat the condition for which the compound has been requested; AND

  4. The compound does not contain any product(s) that were withdrawn or removed from the market due to safety reasons; AND

  5. The compound is not used for, nor does it contain, a product that is indicated for an excluded benefit (e.g., cosmetic)

Additionally, authorization may be placed to allow access to the prescription benefit for products that are not considered standard coverage (e.g. drugs administered intravenously) when all the following are met:

  1. All of the above criteria are for medically necessary are met for the compounded product; AND

  2. The product is being used in a compound that will be administered through a route that is considered standard coverage for the prescription benefit (e.g., oral, topical, inhalation, etc.). Bladder installation may be considered if the above criteria are met.

Authorization length for short supply of the commercially available product will be six months.All other authorizations: 2 years

http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm

* http://www.ashp.org/Drug-Shortages/Current-Shortages


 


See labeling for specific ingredients used in a compound.


American Pharmacists Association. Frequently Asked Questions About Pharmaceutical Compounding. Available from: http://www.pharmacist.com/frequently-asked-questions-about-pharmaceutical-compounding. Accessed June 22, 2023.

ASHP Guidelines on Outsourcing Sterile Compounding Services. January 2014. Available from:  http://www.ajhp.org/content/71/2/145?sso-checked=true.  June 22, 2023.

International Academy of Compounding Pharmacist. Available from: http://www.iacprx.org/. Accessed June 22, 2023.

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug and Cosmetic Act. December 2016. Available from:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act . Accessed  June 22, 2023.

Pharmacy Compounding of Human Drug Products Under Section 503B of the Federal Food, Drug and Cosmetic Act. January 2018. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510153.pdf. Accessed  June 22, 2023.

Report: Limited FDA Survey of Compounded Drug Products. June 2018. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm, Accessed  June 22, 2023.

USP Compounding Standards and Resources.  Available from: http://www.usp.org/usp-healthcare-professionals/compounding?gclid=CJfWt97qmsECFedzMgodCzgA_w. Accessed June 22, 2023.


126/8/20236/8/202410/1/2023 1:24 AMNo presence informationsrv_ppsgw_P

Off Label Use Policy (Rx.01.33)

Note: All routes of administration listed may not be covered under the pharmacy benefit, e.g. intravenous, intramuscular.

 

P​roduct

Description

Compound claims greater than $75

compound where the submitted claim cost is greater than or equal to $75

Various

Compounding kit

417
  
7/1/2024Rx.01.218CommercialOyenusi, OluwadamilolaQ1-2024
The Continuous Glucose Monitors (CGMs) are indicated for use in individuals with type 1 diabetes who require insulin and need to be monitored for unexplained glycemic fluctuations and hypoglycemic unawareness. Hypoglycemic unawareness is the inability of an individual to notice and recognize symptoms of hypoglycemia while they are experiencing them.

CGMs devices are considered an adjunct to be used with a traditional blood glucose monitor. These adjunctive devices allow individuals to track glucose levels and detect episodes of high and low blood sugar in real-time on an ongoing basis. The device consists of a disposable subcutaneous sensor, an external transmitter, and an external receiver (monitor), which can be a stand-alone device or built into an insulin pump. Sensors are worn as indicated by the device manufacturer in accordance with US Food and Drug Administration (FDA) labeling and are replaced on an ongoing basis.

Depending on the device sensor longevity capability, a CGMs sensor measures interstitial glucose levels for 6 to 14 days. Use of this device requires the glucose sensor to be implanted subcutaneously, usually in the abdomen or in an area above the buttocks. The transmitter is connected to the sensor by an adhesive patch, and glucose signals are sent from the sensor to the receiver every five minutes. Interstitial glucose values appear on the receiver or mobile device, where they can be read and reviewed by the individual. This data may be stored and downloaded for analysis. CGMs devices also allow for customization of threshold settings, such as alarms, to detect high and low glucose levels.

The FDA has approved several CGMs devices to assist in analyzing glycemic trends in the ongoing evaluation and management of individuals with diabetes. The FDA requires that alterations to an individual's insulin dosage or therapy are made only after confirmation of blood glucose levels with a traditional blood glucose monitor.
The intent of this policy is to communicate the medical necessity criteria for Continuous Glucose Monitors (Dexcom®, Medtronic®, Freestyle Libre) as provided under the member's prescription drug benefit.

INITIAL CRITERIA: Continuous glucose monitor (CGM) products (receivers, transmitters and sensors) are approved when ALL of the following are met:

  1. Diagnosis of diabetes; and
  2. Member is adherent to current diabetes treatment plan and participates in ongoing diabetes education and support; and
  3. One of the following:
    1. Member is treated with insulin; or
    2. Member is non-insulin treated and experiences significant hypoglycemia (e.g., recurrent, unexplained, severe [generally blood glucose levels <50 mg/dL] hypoglycemia or hypoglycemic unawareness).; and
  4. For Freestyle Libre only, submission of documentation (e.g., chart notes) or paid claim history showing member had a minimum 90-day trial of Dexcom within the last 180 days

Initial authorization duration: 2 years.


REAUTHORIZATION CRITERIA: Continuous glucose monitor (CGM) products (receivers, transmitters and sensors) are approved when ALL of the following are met:

  1. Documentation that of a positive clinical response as evidenced by ONE of the following:
    1. Improvement in glycemic control (e.g., lower and/or maintain A1C levels); or
    2. Reduction or improvement in hypoglycemic events
  1. For Freestyle Libre only, submission of documentation (e.g., chart notes) or paid claim history showing member had a minimum 90-day trial of Dexcom within the last 180 days

 

Reauthorization duration: 2 years


None

Dexcom® CGM. Available at: https://www.dexcom.com/continuous-glucose-monitoring. Accessed April 17, 2024.

Freestyle Libre® CGM. Available at: https://www.freestyle.abbott/us-en/home.html. Accessed April 17, 2024.

Medtronic® CGM. Available at: https://www.medtronicdiabetes.com/treatments/continuous-glucose-monitoring. Accessed April 17, 2024.

Weinstock, R. Management of blood glucose in adults with type 1 diabetes mellitus. UpToDate website. Updated February 2021 www.uptodate.com. Accessed April 17, 2024.


73/14/20249/14/20247/1/2024 1:29 AMNo presence informationsrv_ppsgw_P
Rx.01.33 Off-Label Use 

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit

Dexcom® line of products

Medtronic® line of products

Freestyle® line of products

Dexcom® G5 Receivers

Dexcom® G6 Receivers

Dexcom® G7 Receiver

Dexcom® G5 Sensors

Dexcom® G6 Sensors

Dexcom® G7 Sensor

Dexcom® G5 Transmitter Kit

Dexcom® G6 Transmitter Kit

Guardian™ Connect Transmitter

Guardian™ Sensor

Enlite® Sensor

Eversense® Sensor/Holder

 

 

 

Freestyle Libre® 14 Day Reader

Freestyle Libre® 14 Day Sensor

Freestyle Libre® 2 Reader

Freestyle Libre® 2 Sensor

Freestyle Libre® 3 Sensor

 


NANA
255
  
10/1/2023Rx.04.3Claim Payment PolicyOyenusi, Oluwadamilola

​Convenience packs combine two or more individual drug products into a single package.  Products included in a convenience pack may include prescription products, over the counter products, and/or products not approved by the Food and Drug Administration (FDA).   

​The intent of this policy is to communicate the coverage position of convenience packs.

 

Coverage is subject to the terms, conditions, and limitations of the member's contract.

Convenience packs as described above are not covered under the pharmacy benefit because each product is available independently.

A prescriber may issue a prescription or prescriptions for the individual components of the convenience pack.  The individual components will be covered pursuant to the terms of member's benefit.

Examples of convenience packs include, but are not limited to:

  • DermacinRx Clorhexacin, which contains the following:
    • Mupirocin 2% ointment – covered as a pharmacy benefit
    • Chlorhexidine gluconate 4% solution, dimethicone 5% cream not covered (not an FDA approved product)
  • Diclovix DM PAK 1.5-8% which contains the following:
    • Diclofenac sodium solution 1.5% - covered as a pharmacy benefit
    • Menthol gel 8% therapy pack – not covered (not FDA approved product)​​



​N/A

96/8/202410/1/2023 1:25 AMNo presence informationsrv_ppsgw_P

​Non-FDA approved Products Rx.04.2

Off-Label Use Rx.01.33

 
341
  
4/1/2024Rx.04.9Claim Payment PolicyOyenusi, OluwadamilolaQ4-2023
​A cosmetic drug is intended to be used for cleansing, beautifying, promoting attractiveness, or altering the appearance of human body from which no significant improvement in physiologic function can be expected. 
The intent of this policy is to communicate the coverage of cosmetic drugs under the member’s prescription drug benefit.

Coverage is subject to the terms, conditions, and limitations of the member's contract.
Cosmetic drugs, or drugs prescribed for cosmetic purposes, are not covered under the pharmacy benefit. Cosmetic drugs or drugs prescribed for cosmetic purposes are:

  • Used for other than the treatment of illness, injuries, congenital birth defect or restoration of physiological function; and
  • Used for cleansing, beautifying, promoting attractiveness or altering the appearance of any part of the human body


 
Examples of drugs prescribed for cosmetic use include, but are not limited to:

Brand Name         Generic Name   FDA Indication     
EgriftaTesamorelinReduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Renova, Refissa (branded product only)TretinoinAdjunctive agent for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who do not achieve such palliation using comprehensive skin care and sun avoidance programs alone
Propecia 1mgFinasteride 1mgMale pattern alopecia
Multiple (e.g., Lustra)HydroquinoneDiscoloration of skin; Hyperpigmentation of skin
Latisse 0.03% solutionBimatoprostHypotrichosis of the eyelashes
Vaniqa 13.9% creamEflornithineReduction of unwanted facial hair in women
Multiple (e.g., Rogaine)Minoxidil topicalMale pattern alopecia; hair regrowth in women

N/A
412/18/202312/18/20244/1/2024 1:23 AMNo presence informationsrv_ppsgw_P

Rx.01.2 Applicable Age Edits 

Rx.01.33 Off-Label Use 

Rx.01.202 Prior Authorization Requirements for Select Drugs 

12.01.03a​ Cosmetic Procedure medical policy 


cosmetic drugscosmetic drugs
302
  
1/1/2024Rx.01.132CommercialOyenusi, Oluwadamilola

Cushing's disease is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary tumor.  Surgical intervention is required for optimal treatment of Cushing's disease.  When surgery is delayed, contraindicated, or unsuccessful, medical therapy may be required.  Cabergoline and pasireotide are medications that target the tumor and may help normalize urinary free cortisol.

Pasireotide (Signifor®) exerts its pharmacological activity via binding to somatostation receptors (SSTRs). Pasireotide binds and activates the SSTRs, resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion. 

Osilodrostat (Isturisa®) is a cortisol synthesis inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland.

Mifepristone (Korlym®) is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.

Levoketoconazole (Recorlev®) inhibits key steps in the synthesis of cortisol and testosterone, principally those mediated by CYP11B1 (11β hydroxylase), CYP11A1 (the cholesterol side-chain cleavage enzyme, the first step in the conversion of cholesterol to pregnenolone), and CYP17A1 (17α-hydroxylase).

Pasireotide (Signifor®) is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. 

Osilodrostat (Isturisa®) is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

Mifepristone (Korlym®) indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Levoketoconazole (Recorlev®) is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative

The intent of this policy is to communicate the medical necessity criteria for pasireotide (Signifor®), osilodrostat (Isturisa®), mifepristone (Korlym®), and levoketoconazole (Recorlev®) as provided under the member's prescription drug benefit.

Cushing's Disease

INITIAL CRITERIA Pasireotide (Signifor®) or osilodrostat (Isturisa®) is approved when ALL of the following are met:

  1. Diagnosis of Cushing's disease; and
  2. Member has failed surgery or is not a candidate for surgery; and
  3. Member is 18 years of age or older; and
  4. Prescribed by or in consultation with an endocrinologist; and
  5. For Osilodrostat (Isturisa®) only, inadequate response or inability to tolerate pasireotide (Signifor® [LAR])

Initial Authorization duration: 6 months

REAUTHORIZATION CRITERIA Pasireotide (Signifor®) or osilodrostat (Isturisa®) is re-approved when ALL of the following are met:

  1. Documentation of positive clinical response to therapy (i.e., reduction in cortisol levels, improvement in signs or symptoms of the disease); and
  2. Prescribed by or in consultation with an endocrinologist

Reauthorization duration: 2 years

INITIAL CRITERIA Levoketoconazole (Recorlev®) is approved when ALL of the following are met: 
  1. Diagnosis of Cushing’s syndrome; and 
  2. Member is 18 years of age or older; and 
  3. Member is being treated for endogenous hypercortisolemia (e.g., pituitary adenoma, ectopic tumor, adrenal adenoma); and
  4. One of the following:
    1. Member is not a candidate for surgery; or
    2. Surgery has not been curative; and
  5. Inadequate response or inability to tolerate oral ketoconazole; and
  6. Prescribed by or in consultation with an endocrinologist

Initial authorization duration: 12 months

REAUTHORIZATION CRITERIA Levoketoconazole (Recorlev®) is re-approved when there is documentation of positive clinical response to therapy as demonstrated by one of the following:
  1. Normalization of urinary free cortisol (UFC); or
  2. At least a 50% decrease in UFC levels
Reauthorization duration: 2 years

Hyperglycemia secondary to Cushing's Syndrome

INITIAL CRITERIA Mifepristone (Korlym®) is approved when ALL of the following are met:

  1. Hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance; and
  2. Member has failed surgery or is not a candidate for surgery; and
  3. Prescribed by or in consultation with an endocrinologist; and
  4. Member is not pregnant; and
  5. Member is 18 years of age or older

Initial Authorization duration: 6 months

REAUTHORIZATION CRITERIA Mifepristone (Korlym®) is re-approved when ALL of the following are met:

  1. Documentation of positive clinical response to therapy (e.g., improved, or stable glucose tolerance while on therapy); and
  2. Prescribed by or in consultation with an endocrinologist

Reauthorization duration: 2 years
 

Mifepristone (Korlym®)

TERMINATION OF PREGNANCY

Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively.  The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with KORLYM and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

Levoketoconazole (Recorlev®)

HEPATOTOXICITY AND QT PROLONGATION

Cases of hepatotoxicity with fatal outcome or requiring liver transplantation have been reported with oral ketoconazole. Some patients had no obvious risk factors for liver disease.RECORLEV is associated with serious hepatotoxicity. Evaluate liver enzymes prior to and during treatment.

RECORLEV is associated with dose-related QT interval prolongation. QT interval prolongation may result in life threatening ventricular dysrhythmias such as torsades de pointes. Perform ECG prior to and during treatment.

Nieman LK. Medical therapy of hypercortisolism (Cushing's syndrome). UpToDate. August 2022. Available at: https://www.uptodate.com/contents/medical-therapy-of-hypercortisolism-cushings-syndrome?source=search_result&search=cushings%20disease&selectedTitle=8~100#H1. Accessed December 05, 2023.

 

Nieman LK. Overview of the treatment if Cushing's syndrome. UpToDate. November 2021. Available at: https://www.uptodate.com/contents/overview-of-the-treatment-of-cushings-syndrome?source=search_result&search=cushings%20disease%20management&selectedTitle=1~100#H4. Accessed December 05, 2023.

 

Isturisa® (osilodrostat) [prescribing information]. Lebanon, NJ: Recordati Rare Disease, Inc.; March 2020. Available from: https://www.isturisa.com/pdf/isturisa-prescribing-information.pdf. Accessed December 05, 2023.

 

Korlym® (mifepristone) [prescribing information]. Menlo Park, CA: Corcept Therapeutics Inc.; November 2019. Available from: https://www.korlym.com/wp-content/uploads/2018/01/K-00017-NOV-2019_electronic-PI_r8_FINAL.pdf. Accessed December 05, 2023.

 

Recorlev® (levoketoconazole) [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.; December 2021. Available from: https://www.recorlev.com/full-prescribing-information.pdf. Accessed December 05, 2023.

 

Signifor® (pasireotide) [package insert]. East Hanocer, NJ. Novartis Pharmaceuticals Corporation. June 2020. Available at: https://www.signiforlar.com/pdf/signifor-lar-pi.pdf. Accessed December 05, 2023.​

 



129/14/20239/14/20241/1/2024 1:25 AMNo presence informationsrv_ppsgw_P
 Off-Label Use policy Rx.01.33
 

​Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit Rx.01.76


 

Brand nameGeneric name
Signifor®Pasireotide
Isturisa®Osilodrostat
Korlym®
Mifepristone
Recorlev®Levoketoconazole

308
  
1/1/2024Rx.01.181CommercialOyenusi, Oluwadamilola

Cells that rapidly divide such as bone marrow and myeloid cells require vitamin B12 to mature and proliferate. Vitamin B12 is necessary for hematopoiesis, nucleoprotein synthesis, and myelin synthesis.  Additionally, it is required for fat and carbohydrate breakdown and protein synthesis. Vitamin B12 is bound to protein rich foods and comes from the diet. Hydrochloric acid and gastric protease break it down into its free form. The free form of vitamin B12 must be combined with intrinsic factor, which is produced by gastric parietal cells, in order to be absorbed in the distal ileum. Pernicious anemia is an autoimmune disease that is associated with the destruction of the parietal cells that secrete intrinsic factor.  The inability to absorb vitamin B12 results in a severe deficiency which, if left untreated, can lead to megaloblastic anemia, GI lesions, or neurologic defects.

Cyanocobalamin is the most widely used form of vitamin B12 to treat and maintain normal hematologic status in patients with pernicious anemia. It has identical hematopoietic activity to the anti-anemic factor that is present in the liver. Cyancobalamin is also indicated as a supplement for other vitamin B12 deficiencies, such as dietary deficiency and malabsorption of vitamin B12,

Cyanocobalamin is available in oral, sublingual, and injection dosage forms. Cyanocobalamin nasal spray, a new route of administration, provides an alternative route of administration for vitamin B12 deficiency.

Cyanocobalamin inhalation (Nascobal®) is indicated for:

  1. Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement.
  2. Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia.
  3. Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal.


 

The intent of this policy is to communicate the medical necessity criteria for cyanocobalamin inhalation (Nascobal®) as provided under the member's prescription drug benefit.

INITIAL CRITERIA Cyanocobalamin inhalation (Nascobal®) is approved when ALL of the following are met:

  1. Diagnosis of ONE of the following:
    1. Pernicious anemia in members requiring maintenance therapy who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement; or
    2. Dietary deficiency of vitamin B12 due to strict vegetarian diet; or
    3. Malabsorption of vitamin B12 due to a structural or functional damage to the stomach or ileum; or
    4. Inadequate secretion of intrinsic factor; or
    5. Competition for vitamin B12 by intestinal parasites or bacteria (e.g., tapeworm, blind loop syndrome); or
    6. Inadequate utilization of vitamin B12 (e.g., antimetabolites are employed in treatment of neoplasia); and
  2. Member is 18 years of age or older; and
  3. Inadequate response or inability to tolerate oral and sublingual cyanocobalamin
     

Initial authorization duration: 6 months

REAUTHORIZATION CRITERIA Cyanocobalamin inhalation (Nascobal®) is re-approved when there is documentation of positive clinical response to therapy.

Reauthorization duration: 2 years

​N/A

 

Nascobal (cyanocobalamin inhalation) prescribing information. Spring Valley (NY). Par Pharmaceutical Companies, Inc. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021642Orig1s015lbl.pdf. Revised November 2018. Accessed November 15, 2023.

National Institutes of Health: Vitamin B12 Dietary Supplement Fact Sheet [Internet]. Bethesda (MD):National Institutes of Health; [updated 2020 March 30]. Available from: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/. Accessed November 15, 2023.

Schrier SL. Clinical manifestations and diagnosis of vitamin B12 and folate deficiency. UpToDate website. Last updated September 29, 2022. Available at: http://www.uptodate.com/. Accessed November 15, 2023.

Schrier SL. Causes and pathophysiology of vitamin B12 and folate deficiencies. UpToDate website. Last updated June 16, 2021. Available at http://www.uptodate.com/ Accessed November 15, 2023.​




 

99/14/20239/14/20241/1/2024 1:25 AMNo presence informationsrv_ppsgw_P

Off-Label Use Rx.01.33


Brand Name

Generic Name

Nascobal

Cyanocobalamin


273
  
10/1/2023Rx.01.263CommercialOyenusi, Oluwadamilola

Vernal keratoconjunctivitis (VKC) is an allergic inflammation of conjunctiva that is bilateral and usually seasonally recurrent. There are three types of vernal conjunctivitis: palpebral (papillae primarily involving upper tarsal conjunctiva), limbal (papillae located at limbus), and mixed (components of both palpebral and limbal types). Histopathologic exam of affected conjunctiva shows small lymphoid follicles composed of increased mast cells, eosinophils, and lymphocytes, mononuclear cells and macrophages, CD4 T lymphocytes and B lymphocytes, fibroblasts, and newly secreted collagen (extracellular matrix components). As disease progresses, cellular infiltration and new collagen deposition form giant papillae (squamous epithelial hyperplasia and dense fibrous tissue containing inflammatory cells). Inflammation of limbal palisades and tarsal conjunctiva produces nodules, due to firm attachments of conjunctiva.

Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically. Following ocular administration, cyclosporine is thought to act by blocking the release of pro-inflammatory cytokines such as IL-2. The exact mechanism of action in the treatment of VKC is not known.

Verkazia® ophthalmic emulsion is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.


​The intent of this policy is to communicate the medical necessity criteria for Cyclosporine (Verkazia®) as provided under the member's prescription drug benefit. 

INITIAL CRITERIA Cyclosporine (Verkazia®) is approved when ALL of the following are met:

  1. Diagnosis of moderate to severe vernal keratoconjunctivitis confirmed by the presence of clinical signs and symptoms (e.g., itching, photophobia, giant papillae at the upper tarsal conjunctiva or at the limbus, thick mucus discharge, conjunctival hyperaemia); and
  2. Member is 4 years of age or older; and
  3. Inadequate response or inability to tolerate one of the following:
    1. Topical ophthalmic “dual-acting” mast cell stabilizer and antihistamine (e.g., olopatadine, azelastine); or
    2. Topical ophthalmic mast cell stabilizers (e.g., cromolyn); and
  4. Inadequate response or inability to tolerate short term use (up to 2 to 3 weeks), of topical ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluoromethalone); and
  5. Prescribed by or in consultation with one of the following:
    1. Ophthalmologist or
    2. Optometrist

Initial authorization duration: 6 months

REAUTHORIZATION CRITERIA Cyclosporine (Verkazia®) is re-approved when there is documentation of positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms (e.g., itching, photophobia, papillary hypertrophy, mucus discharge, conjunctival hyperaemia).

Reauthorization duration: 2 years



​N/A

DynaMed. Vernal Keratoconjunctivitis. EBSCO Information Services. https://www.dynamed.com/condition/vernal-keratoconjunctivitis. Accessed June 23, 2023.

 

Verkazia® (cyclosporine) [package insert]. Emeryville, CA: Santen Incorporated; June 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214965s000lbl.pdf. Accessed June 23, 2023.​




26/8/20236/8/202410/1/2023 1:28 AMNo presence informationsrv_ppsgw_P

Rx.01.33 Off Label Use

Rx.01.76 Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit



Brand NameGeneric Name
Verkazia®Cyclosporine


1 - 30Next